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Abstract  
Summary of Objectives: 
Neurodegeneration is an important pathological component hallmark of many neurological illnesses. 
Effective management demands a greater understanding of the changes taking place at a neuronal 
level.  
In this thesis I have investigated the biochemical changes at the cellular level in four conditions 
associated with neurodegneration – traumatic brain injury (TBI), prion disease, posterior cortical 
atrophy (PCA) and Parkinson’s disease (PD).  Positron Emission Tomography (PET) scanning was 
my main investigative tool. 
Each condition was investigated using up to four different radioactive PET ligands: 
1. [11C]-PIB, to measure beta amyloid load and detect other β sheet folded proteins in the 
brain, 
2. [11C]-PK11195, to quantitate microglia activation in the brain, 
3. [18F]-FDG, to investigate changes in the pattern of cerebral glucose metabolism, and 
4. [11C]-SCH442416, used specifically in PD to investigate changes in striatal adenosine 2A 
receptor concentrations.  
Subjects also underwent MRI scanning. Neuropsychological assessments were conducted on TBI 
subjects in an attempt to correlate any PET changes with clinical findings. 
Summary of Results: 
Subjects with chronic TBI demonstrated increased [11C]-PK11195 uptake in subcortical structures 
including the thalamus and putamen distant from the original focal brain lesion. Processing speed in 
TBI subjects was positively correlated with thalamic [11C]-PK11195 uptake.  [11C]-PIB PET did not 
show a significant increase in signal compatible with amyloid deposition following TBI. In prion 
disease there was no increased uptake of [11C]-PIB although prion protein form beta pleated 
sheets. In PCA there is reduced parieto-occpital [18F]-FDG signal despite the [11C]-PIB pattern of 
binding being more typical of Alzheimer’s Disease. Adenosine 2A receptor availability was 
significantly raised in the striatum of PD patients with levodopa induced dyskinesias. 
These studies suggest that amyloid plaque deposition may not be the driving force of neuronal 
damage while microglial deactivation may play a leading role in driving disease. My work also 
suggests there is deregulation of adenosine transmission in dyskinetic PD and that A2A adenosine 
blockade may have therapeutic potential. 
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1.1 Introduction 
The world’s population is getting older. Improved treatments for cardiovascular, respiratory 
and metabolic conditions have meant that people are staying healthier for longer. One can 
however argue that as people age, neurological health and the maintenance of cognitive 
ability remains an important part of wellbeing. While a definitive cure for any form of 
neurodegeneration seems some time off our knowledge of these conditions is continuously 
expanding. 
 
Effective control of the motor manifestations of conditions like Parkinson’s disease (PD) has 
improved survival by years, even decades. Other conditions like Alzheimer’s disease (AD) 
and prion disease are more resistant to control with the latter thought to be resistant to any 
form of pharmacotherapy. 
 
Our understanding of cognitive decline in neurodegeneration is still in its infancy and more 
work needs to be done. In this thesis I will be investigating different forms of 
neurodegeneration. While the overriding emphasis will be on conditions fitting under the 
umbrella of AD, I will also be investigating PD. With the latter, I would like to investigate how 
a condition intimately linked to the dopamine pathway may be affected by failure of other, 
specifically the adenosine, neurotransmitter systems. 
I will be thus focusing on four imaging modalities: 
1. β amyloid plaque imaging, 
2. Imaging of activated microglial cells, 
3. Imaging of cerebral metabolism and 
4. Adenosine2A (A2A) receptor imaging specifically in PD. 
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These investigations will help link amyloid pathology and inflammation to conditions 
predisposing to dementia and improve our understanding of how cognitive impairment 
develops and progresses. A range of subjects with varying degrees of impairment will be 
recruited. The demonstration of amyloid pathology and inflammation in these conditions may 
support usefulness of novel anti-amyloid and anti-inflammatory treatment strategies in these 
conditions. My investigations in A2A receptors in PD will help strengthen the increasing 
evidence of the importance of adenosine in the control of PD. 
 
1.2 Positron Emission Tomography 
In this section I will be outlining the physics underlying and usefulness of the imaging 
technology Positron Emission Tomography (PET). 
 
One of the first medical applications of PET scanning was in the imaging of cerebral tumors 
in 19511. This was performed by the group at the Massachusetts General Hospital making 
use of the positron emitter [74As]. They found that patients with tumor recurrence had an 
“unbalanced” scan with increased counts either towards or away from a pair of detectors.  
Other positron emitting isotopes were subsequently developed including [11C] (t1/2 20 mins), 
[15O] (t1/2 2 mins), and [18F] (t1/2 110 mins). These were incorporated into molecules and 
drugs to form radiotracers with known biological properties. 
 
At the heart of positron emitting radionuclides is a proton rich nucleus1,2. It achieves stability 
by converting a proton into a neuron and releasing the residual positive charge as a positron. 
This particle has specific well defined properties and has an equivalent in mass to an 
electron. The result of this decay is the loss of positive charge by the atom. A single electron 
must then be ejected from the atom to balance its charge. This is achieved by a process 
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called “internal conversion” where upon the nucleus supplies energy to an orbiting electron 
to overcome the binding energy hence providing it with enough kinetic energy to leave the 
atom. The result is the ejection of a positron and an electron from the atom leaving it at least 
2 electron masses lighter than the parent atom. 
 
The ejected positron becomes deflected from its original path as it interacts with surrounding 
nuclei and electrons. This interaction can be one of four types: 
1. Inelastic collisions with atomic electrons – this is the most common method of loss of 
kinetic energy, 
2. Elastic scattering with atomic electrons – the positron is deflected but energy and 
momentum are conserved, 
3. Inelastic scattering with a nucleus – the positron is deflected often with the emission 
of Bremsstrahlung radiation3 (electromagnetic radiation released when charged 
particles with large energies, compared to their rest energies, decelerate over a very 
short distance) and 
4. Elastic scattering with a nucleus – the positron is deflected but does not radiate any 
energy or transfer energy to the nucleus. 
 
With its kinetic energy expended the positron comes to rest within 2-6 mm and then 
combines with a neighboring electron to form a metastable intermediate species call a 
positronium. This particle has a mean life span of about 10-7 second. This annihilation event 
is coupled to the release of electromagnetic radiation in the form of two gamma ray photons 
of 0.511MeV (the rest mass equivalent of each particle). The photons should be released at 
180o to one another in order to conserve momentum which is close to zero at the time of 
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annihilation. See figure 1.1. However, the release of the pair of photons is not exactly 180o to 
each other due to both the uncertainty principle and also to the non-zero momentum of the 
positron – electron pair at the time of annihilation. In <1% of instances 3 photons of energy 
(instead of 2), are released. 
 
Positron annihilation and gamma photon emission thus takes place a finite distance away 
from the parent atom. For [18F] the positron travels around 2mm before annihilation but with 
a high energy positron, such as released by [82Rb], this can be as much as 5.9mm1. The 
implication of positron travel prior to annihilation is a reduction in the spatial resolution of a 
PET scan. The calculation of the point of annihilation also relies heavily on two photons 
being emitted at 180o to each other. If this angle deviates to some extent the resolution of 
the PET scan is again adversely affected. 
 
Along with the development of new tracers, scanner technology has also improved from the 
first one dimensional scanners of the 1950’s to the three dimensional scanners used today. 
Many machines employ a 15 cm long cylinder of detectors containing the crystal bismuth 
germanate Bi4(GeO4)3 (BGO). This crystal scintillates emitting visible light when struck by 
gamma 511 keV radiation and is coupled to photo-detectors responsible for the detection 
and amplification of visible light. A photon of energy colliding with the BGO crystal results in 
the production of visible light which is then collected and amplified. The annihilation of a 
single positron in most instances results in two oppositely sited photo-detectors being 
activated within nanoseconds of one another in the field of view of the PET scanner. This 
annihilation coincidence detection allows the locations of positron emissions to be computed. 
Random coincidences can also occur if two unrelated photons strike opposing detectors at 
similar times apparently coming from a single coincidence. See figure 1.2. The random 
coincidence rate of a PET scanner is proportional to 2tA2. In this estimation t is the 
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coincidence window width or the maximum width of time between two detectors being 
activated allowing it to be linked to a single coincidence and A is the event rate or activity 
present at each detector in the scanner field of view. PET data can be collected during the 
scan to estimate the level of random coincidences and a correction applied to negate their 
effect.  In this thesis the Siemens ECAT 962 scanner was used. It has an axial view of 
15.5cm with a maximum resolution of 2.42mm x 2.42mm x 2.092mm. This scanner has been 
used in previous studies in AD and PD providing a library of control and patient PET scans 
for comparison. 
 
1.3 PET radiotracers 
There has been rapid development of PET tracers over the recent years. For this thesis most 
of the tracers used had a proven track record, reliable production and availability. In 
investigating the A2A receptor, I however used a radiotracer whose use in humans and 
production is less well described. [11C] containing compounds were produced on site by 
Hammersmith Imanet while [18F] containing compounds were purchased from a local 
supplier. 
 
In vivo amyloid imaging was performed with [11C]-PIB PET, chemical name {N-methyl 11C-
}2-(4’-methylamino-phenyl)-6-hydroxy-benzothiazole4,5. This marker is a neutral thioflavin-T 
analogue with nanomolar affinity for fibrillar beta amyloid. It has been used extensively for 
imaging amyloid in AD and cognitive impairment6-8. As a thioflavin-T derivative, 11C-PIB 
might also be expected to bind to prion protein amyloid aggregates present in Creutzfeldt-
Jakob disease. Its usefulness in this scenario has not been systematically tested. 
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The identification of activated microglia depends on detection of proteins expressed by these 
cells as they change from their resting state to becoming phagocytic. The mitochondria of 
activated microglia express a cholesterol transporter known as the translocator protein 
(TSPO). The isoquinoline carboxamide ligand [11C] -PK11195, chemical name N-butan-2-yl-
1-(2-chlorophenyl)-N-methylisoquinoline-3-carboxamide, selectively binds to TSPO making it 
a useful marker of activated microglial cells6,8. TSPO is, however, also expressed by 
endothelial cells which also bind [11C]-PK11195. Brain uptake can be contaminated with a 
vascular signal making analysis of uptake kinetics more complex. In these studies I 
employed an in-house specialized software, SuperPK, which uses cluster analysis to 
kinetically separate and correct brain signals for vascular binding.  This will be discussed 
further later on. 
 
[18F]-FDG, chemical name [18F]-2-fluoro-2-deoxyglucose is a glucose analogue where the 
2’ hydroxyl group (-OH) is replaced by 18F. The half-life of 18F is 109.8mins radioactively 
degrading to 18O. [18F]-FDG is taken up by metabolically active cells and phosphorylated to 
become [18F]-FDG-6-phosphate. The latter becomes trapped within these cells as it cannot 
enter the glycolysis pathways until the 2' hydroxyl group is restored by the decomposition of 
18F to 18O and the latter combining with surrounding H atoms. PET studies using [18F]-
FDG, in AD demonstrate reduced uptake in the hippocampus and association cerebral 
cortex8. Brain [18F]-FDG PET can thus be used to demonstrate areas of altered cerebral 
metabolism. 
 
The imaging of the A2A pathway has become possible with the development of [11C]-SCH442,416, 
chemical name 2-(2-furyl)-7-[3-(4-methoxyphenyl)propyl]-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-
c]pyrimidin-5-amine. The use of this tracer is not yet widespread and both patient and control scans 
were performed to enable effective comparisons. To ensure that no assumptions are made spectral 
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analysis will be performed. With this approach, concurrent blood sampling enabled the contribution 
of [11C]-SCH442416 metabolites to radioactive counts to be calculated and accounted for. 
 
1.4 PET image analysis 
Before the analysis of PET data could take place, certain basic preparation steps were undertaken 
to make the data meaningful. These are outlined below along with the technique used for individual 
PET ligand image analysis. 
 
The result of PET scanning is anatomical data of tracer uptake during the entire PET acquisition 
time period. During analysis these dynamic time frames must be combined or added together to 
provide meaningful information on tracer distribution during the PET scan. Time frames that 
provided the highest signal to noise ratio for each particular tracer were chosen. Typically however, 
early time frames consist of mostly noise and were excluded. The result of this combining procedure 
was an “add image” that could in fact be used to grossly identify large cerebral structures. The 
investigations performed in my thesis however required precise anatomical definition of intra-
cerebral structures. All subjects thus had structural MRI performed to provide the anatomical data 
needed for analysis. 
 
MRI’s were performed using either a 1.5 or 3 tesla scanner and the T1 sequence was used as it 
provided the best soft tissue information. The MRI was first segmented into grey matter, white 
matter and CSF. For my investigations, grey matter maps were mostly used but when necessary 
white matter regions were hand drawn. The grey matter map was then registered onto the PET 
scan to provide the anatomy needed.  
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Cerebral structures must then be labelled. In house probability atlases (e.g. the three dimensional 
human brain, Chapter 4, reference 16) generated from anatomical data from a bank of normal 
control MRI scans was used for this purpose. This standard atlas was then applied onto the MRI 
providing the anatomical data used to label the PET scan.  
 
The result of this early stage of analysis was an anatomically labelled PET scan. Importantly, during 
this analysis process the PET data was not modified by any registration or normalisation algorithms 
that could potentially introduce noise to the genuine PET signal.  
 
1.4.1 Generation of the parametric image 
In this thesis I have used different techniques to generate parametric maps based on pre-existing 
evidence in the published literature and its application to the condition being investigated. 
 
In [11C]-PIB and [11C]-SCH442416 analysis cerebellar RATIO images were created for each 
individual subject. The basis of this technique is the lack of pathological changes in the cerebellum 
in many (but not all) neurodegenerative conditions. As a region the cerebellum was thus thought to 
represent background activity against which the rest of the scan could be compared to. 
Standardised cerebellar RATIO images were thus thought to be comparable. 
  
This technique can only be used if there is a viable reference region where we can be certain of a 
lack of tracer binding. In TBI and prion disease, the cerebellum could in fact be involved. In TBI 
parametric [11C]-PIB images were generated by producing standardised uptake values (SUV). SUV 
images were normalised against a factor taking into account the subject body surface area and the 
total amount of radioactivity injected at the start of the PET scan. SUV images can thus be 
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compared. In prion disease, the availability of plasma radioactivity data meant that spectral analysis 
could be performed. This technique makes no assumptions on the number of compartments for 
which tracer distribution takes place and results in the generation of a plasma input function. Using 
this function, parametric images are generated. Spectral analysis was also used to generate the 
parametric image for the [18F]-FDG scans. Maps of regional glucose metabolism were generated 
using a plasma input function reference. This technique will be explained further on.  
 
The generation of the parametric image for [11C]-PK11195 scans was complicated by the 
widespread distribution of this tracer throughout the brain, the cerebral vasculature and the 
musculature. Cluster analysis was used in the generation of the parametric image. This technique 
will be explained further in Chapter 2 but briefly, the reference region was generated by extracting 
from each scan clusters of voxels thought to represent background activity. Images were then 
standardised against these clusters to generate the parametric map.  
 
At the end of this stage of analysis the following images were in place: 
1. PET parametric image, 
2. Registered grey matter map and 
3. Registered labelled atlas. 
 
Using this data I then performed two types of analysis: 
1. Region of interest (ROI) analysis and 
2. Voxel based statistical parametric mapping (SPM) analysis. 
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1.4.2 Region of interest analysis 
In ROI analysis, PET tracer uptake in preselected anatomical regions of the brain were sampled 
compared statically.  The regions chosen were based on previous research and on hypothetical 
models of disease pathology. ROI analysis can thus inform on where PET tracer uptake differs 
statically between control and patient groups. 
 
1.4.3 Voxel based statistical parametric mapping 
In SPM analysis, patient PET scans were normalised into standardised stereotaxic space. The 
result of this step was to help standardise all PET images ensuring all voxel anatomically 
correspond. It could be argued that normalising into standard space introduced significant levels of 
noise. Attempts to overcome this were made by smoothing the images using an isotropic Gaussian 
kernel. Smoothing thus helped to allow for inter-individual anatomical variability and helped improve 
the signal to noise ratio.  
 
Control and patient scans were then grouped together to allow for inter-group comparisons to be 
made. During comparison voxels clusters of a standard size were compared and a t statistic 
calculated. These SPM(t) maps were then displayed on standardised glass brains to enable 
anatomical localisation to take place. The SPM analysis enabled the identification of regions of the 
brain that might of previously have been missed on ROI analysis and can be considered as an 
exploratory form of analysis. See figure 1.4. 
 
In this thesis I used SPM analysis specifically in the analysis of Posterior Cortical Atrophy (Chapter 
4). During this statistical analysis, mean global normalization was omitted as an option. This 
identifies the deviation of SUV voxel values from the reference. Changes in the pattern of binding 
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may actually be obscured by global changes affecting all cortical voxels. This must thus be 
considered as a limitation to this study. 
 
1.5 Dementia as a Syndrome 
Dementia is a clinical syndrome. It is associated with a progressive impairment of multiple 
cognitive functions, including short term recall, affecting the ability to perform activities of 
daily living despite the presence of normal consciousness9. It can result from many different 
diseases all typified by the relentless loss of neurons and neuronal connections. The result is 
increasing difficulty with thinking, attention, and memory accompanied by personality 
change. 
 
Dementia can be further subdivided into cortical, subcortical or mixed depending on the 
region of the brain primarily affected. In cortical dementia there is thinning of the relevant 
cortical grey matter. The most common dementia syndrome worldwide is AD. In AD there is 
selective thinning of the temporo-parietal cortex. However, neuronal loss is not localised to 
the cortex but also targets subcortical areas e.g. the hippocampus and amygdala10,11. The 
subcortical dementias affect the subcortical grey matter structures early in the course of the 
illness. Progressive supranuclear palsy (PSP) and Huntington’s disease (HD) are both 
examples of subcortical dementias.  
 
It must however be remembered that in even in conditions like Parkinson’s disease where 
motor symptoms are most prominent there is cognitive decline with disease progression. AD 
may also exist in conjunction with cerebrovascular disease with the latter contributing to 
cognitive decline. These mixed dementias also include conditions like Creutzfeldt-Jakob 
disease (CJD). Dementia syndromes involve neuronal death. While in vascular dementia the 
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cerebrovascular system is to blame in many other forms of dementia, the cause this demise 
has long been linked to interaction between an abnormally aggregated protein, the target 
neuronal cell and a toxic micro-environment related to microglial activation. 
 
1.5.1 Clinical futures and Natural history 
The symptoms of dementia can be categorised by the presence of the five A’s – Amnesia, 
Aphasia, Agnosia, Apraxia and Agitation (changes in Behaviour)12. Although the features of 
cortical and subcortical dementia differ in accordance to their differing pathologies these 
symptoms tend to all be present but with differing severities. 
 
In sporadic AD, the most common cause of cortical dementia, there is typically a progressive 
impairment of recall. Typically, recent events are not remembered and there may be difficulty 
putting names to faces. Difficulty with word finding, narrowing of the vocabulary and difficulty 
with calculations and arithmetic accompany the amnestic problems. Visuo-spatial awareness 
may become impaired with the development of apraxia. Progression is chronic taking years 
for symptoms to fully evolve. Loss of frontal lobe control may result in inappropriate 
behavior, sexual indiscretion and changes in appetite.  Continued deterioration leads to 
immobility, apathy and mutism. The disease seldom occurs before the age of 45 but the 
incidence rises exponentially after the age of 65. 
 
Apart from the sporadic form of AD there are also monogenic forms typified by earlier onset 
of symptoms and rapid progression associated with mutations in the presenilin or amyloid 
precursor protein genes. There also exists, AD variants such as posterior cortical atrophy 
(PCA) and progressive apraxia and aphasia where presenting clinical features relate to the 
anatomical area initially damaged during the disease course. There is much debate on 
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whether these conditions should actually be considered as different illnesses but 
pathologically they resemble AD and are thought to represent an atypical form of AD. 
 
Traumatic brain injury (TBI) is a common acquired risk factor for the late development of 
AD13. After TBI there is an early rise in levels of the amyloid precursor protein (APP) and an 
intense inflammatory response with the mobilization of microglia to the site of injury and 
active phagocytosis of dead and dying cerebral tissue14. Clinically, TBI can be associated 
with a post concussive syndrome, progressive cognitive decline and late onset seizures after 
recovery from the initial event. Rather than being a single static event TBI seems to kick start 
a cascade of events leading to cerebral damage. It provides a unique opportunity to observe 
this process in action. 
 
The subcortical and mixed forms of dementia vary greatly according to the underlying 
pathology and clinical features relate to the anatomical region of the brain affected. In CJD, 
cerebellar and basal ganglia involvement leads to the motor ataxia and myoclonus. These 
changes are marked by the rapid deposition of mutated prion protein arranged into 
amorphous plaques thought to be responsible for driving degeneration. 
 
1.5.2 Pathology 
The pathological changes in all forms of dementia are linked to the abnormal production and 
aggregation of proteins. The protein constituents vary according the type of dementia and 
the stage of the disease. In sporadic AD beta amyloid plaques and hyperphosphylated tau 
arranged into neurofibrillary tangles (NFT) is a typical finding11. 
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Not surprisingly, initial postmortem investigations in AD focused on the severe end of the 
spectrum. Gross findings revealed a severely atrophied brain with extreme involvement of 
the hippocampus and enthorhinal cortex. Microscopically, characteristic patterns of protein 
deposition have been identified as12,15,16. 
1. Extracellular beta-amyloid protein. This forms diffuse and neuritic fibrillar plaques 
characteristic of AD. These amyloid plaques stain with Congo Red, thioflavine, 
periodic acid – Schiff (PAS) and silver staining methods. Amorphous plaques, seen 
particularly in cerebellum, do not stain with thioflavins. 
2. Hyperphosphorylated microtubular ‘tau’ proteins forming intracellular pairs of helical 
filaments. Filaments form loops, coils and tangled masses within the neuron and are 
known as neurofibrillary tangles (NFT). NFT production and deposition heralds a 
cascade of events leading to neuronal death leaving behind ghost tangles. 
 
The progressive accumulation of these proteins within the brain has different time courses 
and relates differentially to cognitive changes16,17,18. In the Braak staging of AD (1991)19 
amyloid deposition starts first in the cingulate, inferior temporal, and frontal cortex in 
asymptomatic subjects (stage A). This is followed by spread dorsally and posteriorly into 
association neocortical areas (stage B). The subcortical structures and hippocampus are 
then targeted (stage C) as clinical features worsen and time passes. 
 
In early disease NFTs are localised to a single layer of the transenthorhinal region (stage I – 
II). Continued progression involves the entire transentorhinal region and entorhinal cortex 
(stage III – IV). Involvement of the entire entorhinal cortex then follows. Neocortical 
involvement follows including the hippocampus (stage V – VI)20. Clinical deterioration is 
perhaps the most important factor however.  
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The deposition of abnormal protein aggregates is accompanied by widespread microglial 
activation. In their quiescent form microglia are continuously extending their cillary processes 
surveying the brain milieu for changes. This resting population of cells forms the resident 
population of macrophages within the brain. They continuously sample the 
microenvironment around them.  Interactions between the glycoprotein CD200 found on 
neurons and its corresponding receptor on microglial membranes keeps them in this inactive 
state21. Protein aggregation however results in neuronal dysfunction and death resulting in 
the release of adenosine triphosphate (ATP) into the microenvironment of the neuron 
stimulating resting microglia into becoming actively phagocytotic. They change 
morphologically resembling macrophages clearing dead neurons and proteinaceous fibrillar 
debris. Activated microglia also release cytokines including IL-1 and TNF-α. These pro-
inflammatory agents provoke further cytokine release and stimulate the microglia to release 
free radicals including nitric oxide (NO). This in turn causes lipid oxidation, membrane 
damage and DNA disruption. MHC type 2 antigens are expressed by these activated 
microglia. The mitochondria of activated microglia express the cholesterol translocator 
protein – TSPO. TSPO is absent on quiescent microglia and so provides a distinctive marker 
of activated microglia22. The continued and uncontrolled activation of microglia may 
contribute to further neuronal damage and death. Indeed correlations have been found 
between microglial activation and cognitive impairment in mild cognitive impairment 
patients23. 
 
The role of amyloids in dementias is debatable. Further discussions into the role of amyloid 
will follow but is it friend or foe? When does deposition begin during the course of illness? Is 
amyloid most toxic in its monomer/oligomer confirmation, as the amorphous form or as a 
fibrillar plaque?  In certain conditions with AD pathology, amyloid plaque distribution can be 
atypical. For example, in monogenic familial AD, the early distribution of amyloid can differ 
from sporadic AD.  
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The pattern of deposition appears to fall into one of three groups24: 
1. Early involvement of the subcortical grey matter, including the basal ganglia 
2. Diffuse involvement of the cerebellum or 
3. Earlier involvement of the neocortex in a similar pattern to sporadic AD. 
 
PCA is a progressive neurodegenerative condition characterized by early visuospatial 
perceptual problems25. Amyloid deposition can be widespread and has an unclear 
relationship with the cognitive deficit. Early features can include Balint’s syndrome 
(simultanagnosia, ocular apraxia and optic ataxia)26 variably accompanied by the 
Gerstmann’s syndrome, visual agnosia, alexia, agraphia, and transcortical sensory aphasia 
with the later development of memory impairment and features typically associated with AD. 
For this reason PCA has long been considered as an atypical presentation of AD with a 
posterior (occipital) focus of degeneration. This view has been strengthened by postmortem 
studies showing characteristic features of Alzheimer´s disease with senile plaques and 
neurofibrillary tangles. 
 
In vivo imaging studies of PCA are limited and have produced conflicting results27-30. Short 
case series and singe subject case reports have mostly shown similar patterns of amyloid 
plaque deposition in PCA and sporadic AD. This is despite a single study suggesting that 
amyloid plaque deposition has a greater tendency to focus on the posterior parts of the 
brain27. More consistent however is the demonstration of reduced cerebral metabolism in the 
posterior regions of the brain. Only one study currently exists in the published literature 
where both amyloid plaque deposition and cerebral metabolism have been performed on the 
same PCA subjects30. Again no difference in regional plaque deposition binding between 
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PCA and sporadic AD was identified despite a focal reduction in posterior cerebral 
metabolism. 
 
After TBI, there is a greater risk of developing AD later in life. The underlying 
pathophysiology of chronic TBI however remains poorly understood.  Patient outcomes are 
highly variable for reasons that are often unclear. Patients can clinically improve or 
deteriorate years after TBI and may develop unexpected consequences such as post-
traumatic epilepsy or late cognitive decline including Alzheimer’s disease31,32. On-going 
inflammation, driven by unknown factors, may play a significant role. In animal models, the 
initial microglial activation provoked by acute TBI has been shown to persist for at least a 
year33,34. In humans, post-mortem studies have shown microglial activation many years after 
TBI35. At a cellular level one might expect to see accumulation of amyloid plaques alongside 
sustained microglial activation. This remains to be proven in vivo however and this is one of 
the questions I wish to address in this thesis. This would be especially useful as similarities 
between sporadic AD and TBI pathology would suggest that AD management strategies 
may also being applicable to TBI. However, while amyloid precursor protein production is 
increased after TBI, the formation of amyloid plaques is infrequent. 
 
The prion diseases make up a collection of illnesses characterized by the rapid onset of 
dementia associated with other neurological signs and symptoms. The prion protein has 
being identified as the infectious agent36,37. The native protein, cellular prion protein, (PrPc) 
is a normal membrane-bound glycoprotein anchored either by synaptic vesicles or 
endosomal vesicular organelles. It is a metalloprotein thought to be involved in copper 
metabolism. In genetic cases, mutation of this protein results in the creation of PrPsc. 
Microscopic examination of brain sections, demonstrate PrPsc either in plaque or granular 
aggregates. These PrPsc plaques may have similar biophysical properties of amyloid 
30 
 
plaques.  The neuropathology of the prion diseases is highly variable, but certain sub-types, 
particularly Gerstmann-Sträussler-Scheinker syndrome and variant CJD are associated with 
large PrPsc-amyloid plaques. 
 
Unknown however is how PrPsc plaques concentration and distribution changes with 
disease progression. Despite several promising developments in basic science, there is as 
yet no treatment for prion disease that slows or halts the underlying disease process. The 
evaluation of putative therapeutics would benefit considerably from a non-invasive biomarker 
which directly measures the presence and distribution of abnormal PrPsc in the brain. 
 
1.5.3 Management 
As with any chronic incurable condition, the management of dementia has to address the 
needs and wishes of both patients and carers. Issues of capacity may arise as the condition 
progresses and should be addressed earlier on during the course of the illness. In the 
absence of a cure two main symptomatic classes of drugs have been used to improve the 
quality of life of patients11,12: 
1. Cholinesterase inhibitors and 
2. NMDA antagonists. 
Both these agents have been used in the management of AD with moderate success usually 
improving symptoms evidenced by and improvement by 2-3 points on the Alzheimer’s 
Disease Assessment Scale (ADAS-Cog). 
 
The cholinesterase inhibitors include donepezil, galantamine and rivastigmine. As 
cholinesterase inhibitors they increase the concentration of acetylcholine at the cholinergic 
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synapses. Side effects include diarrhea, muscle cramps and fatigue. Their use in the UK is 
limited to mild to moderate AD. Guidelines for their use, in the UK, have been issued by the 
National Institute for Clinical Excellence (NICE)38. 
 
Memantine is a voltage dependent, moderate affinity, non-competitive NMDA receptor 
antagonist. It blocks the effect of pathologically elevated levels of glutamate by preventing 
calcium influx into the neuron. It has been used in AD and vascular dementia. It is generally 
used in more severely affected cases where cholinesterase inhibitors are contra-indicated, 
not tolerated or ineffective. It may also be used in conjunction with cholinesterase inhibitors. 
 
Public health regulations play an important part in controlling conditions like prion disease 
where in the non-genetic or spontaneous forms transmission has been linked to 
contaminated blood products and the use of infected sheep for chicken feed. This has been 
linked to the outbreak of new variant CJD in the UK in the 1990’s. 
 
Dementia management remains a developing field. New immune modulation techniques 
have been developed to aid in the clearance of amyloid plaques from the brains of patients 
with AD.  The usefulness of these treatments is still to be proven, and side effects such as 
micro-haemorrhages, vasogenic oedema and an inflammatory response may limit their 
use39. There is also debate on when treatment is best begun. Current guidelines focus on 
the more severe end of the scale, but it may be that treatment should focus on milder cases 
in an attempt to preserve the already threatened neuronal population. 
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The presence of non-physiologically active protein aggregates link all these conditions. An 
understanding of what is meant by amyloid is however important. I shall now discuss what 
constituent amyloid and how its presence may play a role in neurotoxicity. 
 
1.6 Amyloid 
The role of amyloid in neuro-degeneration is a major focus of my thesis. It is however 
important to have a clear understanding of what amyloid is and the role it plays in dementia. 
The term amyloid, strictly speaking, refers to a group of proteins that conform to a certain 
physical characteristic. They are extracellular deposits of protein fibrils with a characteristic 
appearance under the electron microscope, have a typical X-ray diffraction pattern and an 
affinity for Congo red with concomitant green birefringence40,41. In reality a much broader 
definition of amyloid is usually applied referring to any amorphous aggregate of native or 
recombinant protein. Amyloid aggregates are kinetically stable structures persisting for long 
periods of time and forming visible plaques within tissue. 
 
Amyloid production begins with the synthesis of linear polypeptide chains of amino acids. In 
the case of Alzheimer’s disease β amyloid-40 or -42 are eventually produced. Native 
proteins then undergo tertiary level folding in the endoplasmic reticulum to become 
biologically active. Incorrectly folded proteins are usually not allowed to survive, degraded by 
a complex cellular response involving lysosmes and proteosomes.  However if these 
systems are overwhelmed, inoperable or inhibited the result is the survival of these 
incorrectly folded proteins which aggregate to produce insoluble amyloid. 
 
The typical tertiary structure adopted by amyloid proteins is that of β sheeting – extended 
saw toothed sequences of amino acids with amide bonds almost coplanar and side chains 
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that alternate above and below the plane of the peptide backbone. These parallel or anti-
parallel β sheets are held together by inter-strand hydrogen bonds (see figure 1.5). The β 
sheet conformation usually helps stabilise protein conformations, acting as a scaffold for 
protein-protein and protein-DNA interaction and enabling the further folding of proteins into 
quaternary structures42,43,44. Amyloid proteins are however more prone to forming 
protofilament aggregates.  Protofilaments become arranged helically forming the amyloid 
fibrils identified on electron microscopy. Fibrils are also responsible for the binding Congo 
red dye and producing typical X ray diffraction (see figure 1.6). 
 
1.6.1 Amyloids in Neuropathology 
AD is the most intensely studied of the amyloidoses. The amyloid plaques of AD have been 
the subject of great study since they were first identified on post-mortem studies of AD 
patients by Alois Alzheimer and colleagues. Amyloid plaques can be diffuse fibrillar plaques 
or neuritic plaques which contain fibrils of β-amyloid protein surrounding degenerating nerve 
fibres. Other molecules making up the amyloid plaque include proteoglycans, α1-
antichymotrypsin and apolipoprotein E40,45. 
 
It remains unclear whether β amyloid plaques are neurotoxic or protective in AD, taking toxic 
amyloid oligomers out of circulation. Below I wish to discuss these concepts and ideas 
further. 
 
1.6.2 Physiological role of amyloid precursor protein 
APP is the parent molecule of both sAPPα and β amyloid has varied physiological roles. It is 
a type 1 integral membrane glycoprotein comprising of large N-terminal extracellular domain 
34 
 
and a single transmembrane domain and a short cytoplasmic tail41,46. Within the extracellular 
domain the protein has a cysteine rich terminus followed by an anion region and then a 
neurotrophic region. It is processed post translationally with glycosylation and proteolytic 
cleavage. Ubiquitous throughout the body APP knockout mice revealed reduced body weight 
grip strength, locomotor activity, synaptic transmission, hypersentivity to seizures and 
forebrain commissure defects47. 
 
APP is present as three major isoforms APP770, APP751 and APP69548. The APP695 
isoform is predominant in the brain and it is this isoform to which we refer in the remainder of 
this introduction. It is a membrane bound protein found on many intracellular structures 
including endoplasmic reticulum and the Golgi apparatus but importantly it is also found on 
synaptic and postsynaptic dendrites of axons. 
 
The precise role of APP has not yet been identified but as a large membrane bound protein 
it may in fact function as a G protein coupled receptor46. Binding of an as yet unidentified 
ligand, results in the dissociation of APP into a Gα subunit, Gβl subunit and Go. The result is 
the activation of numerous signalling cascades by these subunits, including adenyl cyclase, 
phospholipase C and voltage dependent calcium channels. 
 
APP also possess several domains that promote binding to specific substrates e.g. heparin, 
laminin and collagen46. This has led to the suggestion that APP also functions as an 
important cell adhesion molecule important in the regulation of neuronal growth and synapse 
formation. 
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Pathology exhibited by APP knockout mice suggests altered neuronal structure and function. 
Changes include gliosis, decreased neocortical and hippocampal levels of synaptopysin, 
reduced dendritic lengths in hippocampal neurones, reduced survival of cultured neurones 
and impaired long term potentiation are present. APP knockout mice however still seem 
capable of learning and only slightly underperform the wild type cohort on learned tasks49. 
This effect could however be secondary to an APP compensatory mechanism involving the 
APP like protein (APLP) type 1 and 2 molecules with the relative deficiency in APP 
becoming more relevant with age. 
 
Despite being a membrane bound receptor molecule APP is acted on enzymatically by 
secretases at 3 sites of cleavage α, β and ϒ. See figure 1.7.  The α site lies relatively close 
to the membrane spanning domain between lysine 613 and leucine 614. The result is the 
formation of a soluble protein 612 amino acid sAPPα. The β site occurs between residues 
596 and 597 of APP695. The result is the production of a 595 amino acid long sAPPβ. 
Interestingly β secretase levels and activity are increased in AD50. It must be noted that the 
production of sAPPα and sAPPβ are mutually exclusive. The remaining membrane bound 
portion of APP known as the carboxy terminal fragment (CFT) also varies in size according 
to the secretase responsible for cleavage. Βeta secretase produces a C99 while α secretase 
results in a marginally shorter C83 product. The activity of ϒ secretase then comes into play. 
This enzyme is responsible for cleaving APP at the carboxyl terminus. The cleavage site is 
located within the APP transmembrane domain. In the case of C99, the result is the 
production of the non-membrane bound Aβ1-40 or Aβ1-42 along with fragments spanning 
Aβ1-39 and Aβ1-43 and the C-terminal fragment. The latter molecule, Aβ1-43, is especially 
important as it forms the nucleus of the amyloid plaques45. C83 component cleavage 
produces a shorter Aβ like fragment called p3 plus the same C terminal fragments. 
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The parent protein APP is thus responsible for generating sAPPα, sAPPβ, Aβ1-40, Aβ1-42, 
p3 and CFT. Such a large group of proteins originating from one source would suggest that 
they have a physiological role. 
 
Neuronal activation of muscarinic acetyl choline receptor (mACh) in hippocampal, striatal, 
cortical and cerebellar slices of rats resulted in increased levels of secreted sAPP 
production51. Certainly sAPP acts as a ligand, binding to LDL receptor related protein. LDL 
binding and regulation is an important part of long term potentiation (LTP) and neuronal 
function. ApoE, another protein linked to LTP can bind sAPP in serum and may regulate its 
clearance52. sAPPα binds to the class A scavenger receptor highly expressed on brain and 
systemic macrophages. Its primary role is clearance of modified and oxidised lipoproteins 
but it can also bind Aβ1-42 microaggregates. sAPP binds to activated kininogen, a protein 
involved in clotting and angiogenesis also found in the brain. sAPP binding to fibulin-1 
activates guanylate cyclase and regulates membrane excitability by regulating calcium 
homeostasis. sAPP thus has many binding sites and is likely to be the principal APP 
fragment involved in memory processing41. 
 
Like other bound proteins, it can be internalised into lysosomes and degraded. sAPP 
activation of guanyl cyclase seems most interesting as it results in the modulation of a GMP 
dependent protein kinase responsible for the modulation of K+ channels that become 
activated during the hyperpolarisation phase of synaptic depolarisation. sAPP also down 
regulates NMDA receptor mediated currents and regulates calcium homeostasis53. Thus 
though a multitude of physiological effects sAPP is able to modulate neuronal activity and 
plasticity. 
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What of the Aβ fragments produced by ϒsecretase activity on the C99 CTF produced by β 
secretase activity? Aβ fragments vary in size from 39 to 43 amino acids. Aβ1-42 aggregates 
more readily than other molecules and levels are increased in AD. The tendency to 
aggregate means Aβ is found not just as monomers but also dimers and oligomers. It is only 
after the formation of oligomers that further aggregation leads to the proto-fibril and fibrils 
that make up the bulk of the amyloid plaque. See figure 1.6. 
 
Unlike the proven physiological importance of APP and sAPP, the Aβ fragments seem to be 
actively cleared rather than taking part in any signalling pathways. Receptors allocated to 
this task include the receptor for advanced glycosylation endproducts (RAGE) and serpin 
enzyme complex receptor (SEC-R)54,55. Aβ may also complete with lipids for binding to ApoE 
thus interfering with neuronal membrane metabolism and interrupt the functioning of the 
mACh receptor found on neurones. It is not surprising that Aβ fragments inhibit hippocampal 
LTP and have a negative effect on memory. These proteins are however physiologically 
active and appear to regulate neuronal function. Aβ solutions containing the Aβ1-42 
component can inhibit LTP in the hippocampus when administered minutes before high 
frequency stimulation. Solutions free of fibrillar Aβ aggregates also inhibited LTP. Careful 
removal of monomers and oligomers however fails to prevent LTP inhibition56. Attention has 
thus been put on oligomers. These species seem responsible for the LTP inhibition. This 
inhibition is not clearly understood but may be secondary to the binding of Aβ to nicotinic 
receptors on pyramidal cells and GABAergic inhibitory interneurons. Activation of the former 
facilitates LTP41. 
 
Brief mention will also be made of tau. Abnormal aggregates of this protein are also found in 
AD. Tau however is independent of APP and Aβ and not found in amyloid plaques. Tau 
protein aggregates are intraneuronal and hyperphosphorylated and are arranged into paired 
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α-helices in AD. Other tauopathies include progressive supranuclear palsy, chronic traumatic 
encephalopathy and fronto-temporal dementia. Native tau protein is an important neuronal 
microtubule-associated protein. Its main role is to stabilise the microtuble system key to 
axonal and dendritic function. Tau microtubules are also found in astrocytes and 
oligodendrocytes. The phosphorylation of tau is a highly regulated process catalysed by 
kinases11,57,58. 
 
Hyperphosphorylation in disease states typically occurs at 30 set points along the tau 
protein. The result is the aggregation of tau into insoluble helices with the disruption of 
micotubular system and death of the host cell. It is still debated whether tau aggregation can 
occur in AD before amyloid plaque deposition has occurred. This question will be of 
increasing importance if it is eventually proven that amyloid plaques formation is actually a 
protective mechanism not directly driving neuro-degeneration. It may in fact prove that tau is 
the provoking protein driving the whole process. 
 
1.7 Levodopa Induced Dyskinesia 
Described thus far have been conditions where cognitive impairment is a significant 
symptom. However it must be remembered that even in conditions like PD, typically 
considered to be a movement disorder, cognitive decline can occur. In fact a person with PD 
is 5-6 times more likely to dement that an age matched controls without PD. My focus 
however will be on the motor aspects of PD. People living with PD at some stage will require 
treatment with dopaminergic drugs. As the condition progresses and doses increase, they 
run the risk of developing levodopa induced dyskinesia (LID)59. With LID there is the 
development of abnormal writhing, involuntary movements linked to dopamine 
administration. LID can be diphasic, related to increasing or decreasing plasma dopamine 
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levels; peak dose dyskinesia, linked to plateau plasma dopamine levels; or off-period 
dystonias, related to dystonic akinesia occurring prior to dopamine administration. 
 
The pathophysiology of LID is thought to be linked to a loss in the feedback mechanisms 
controlling the direct and indirect pathways of the basal ganglia. Components of the complex 
include the globus pallidus interna (GPi), globus pallidus externa (GPe), substantia nigra 
pars reticulata (SNpr), substantia nigra pars compacta (SNpc), subthalamic nuclei (STN) and 
the thalamus. See figure 1.8. Alteration in striatal output to the GPi is a key pathological 
process occurring in Parkinson’s disease and in the development of dyskinesias. Output 
neurones in the striatum express dopamine D1 and D2 receptors and receive a tonic 
dopaminergic input from the SNpc. Output neurones that make up the direct pathway 
express D1 receptors. These neurones transmit GABA, substance P, and dynorphin. 
Dopaminergic input has an excitatory effect on the direct pathway.  Striatal neurones of the 
direct pathway are inhibitory and project directly onto the GPi/SNpr complex. Output 
neurones of the indirect pathway express D2 and A2A receptors. Dopaminergic input here is 
inhibitory. The indirect pathway involves GABA inhibitory projections from the striatum to the 
GPe, GABA inhibitory projections from the GPe to the STN and finally an excitatory 
glutamatergic projection from the STN to the GPi/SNpr. Striatopallidal neurones give rise to 
extensive local collateral axons that arborize with surrounding axons, dendrites and spines. 
It is here that A2A receptors are expressed60-62. These neurones also transmit enkephalin A. 
In PD there is reduced dopaminergic input from the SNpc. The net result is a reduction in the 
activity of the direct and increased activity of the indirect pathways resulting in reduced 
activation of the ventral thalamic nuclei and the motor cortex. Levodopa therapy acts to 
normalise this situation but can overstimulate the direct pathway when dyskinesias occur. 
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The pathogenesis of dyskinesias is also linked to A2A availability in the indirect pathway. 
Here receptors are concentrated along the spinous processes of striato – external pallidal 
neurones and along the collateral feedback branches. The binding of adenosine to these G 
protein linked receptors results in a cascade of reactions that can inhibit or stimulate the 
release of GABA. More clearly defined however, is the antagonistic relationship between D2 
receptor activation and A2A activation which is thought to result in a reduction of the D2 
receptor mediated inhibition of GABA release. Adenosine binding to A2A can also reduce its 
affinity for dopamine by the formation of the D2/A2A complex. 
 
The variable influence of A2A activation on GABA release is also linked to the presence of 
this receptor on the presynaptic striatopallidal membrane and the local collateral feedback 
neurones. Thus while the initial result of increased A2A stimulation may be inhibitory, an 
increase in GABA from collateral neurones will counteract this effect with a reduction in 
GABA release. This precise and delicate balance is disrupted in dyskinetic PD. With 
increased A2A receptor activation there is a reduction in the ability of dopamine to bind to D2 
and variations in the activity of the local collaterals which are normally responsible for 
ensuring a smooth and tonic inhibition of the thalamus. The inhibition of the GPi/SNpr thus 
becomes variable. Dyskinesias result when the inhibitory output from the GPi/SNpr to the 
thalamus is reduced resulting in thalamic over activity and increased motor activity. 
 
The relationship between dyskinesia and A2A receptor availability may be more complex. 
Elevated (pre-proenkephalin) PPE levels are associated with an increased risk of 
development of dyskinesia63. While a causal relationship between dyskinesia and PPE has 
not been demonstrated, elevated PPE-A is responsible for keeping the brain in a primed 
condition for the development of dyskinesia. In MTPT-primate models of PD the pro-
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dyskinesia influence of PPE-A can be inhibited by the use of A2A receptor antagonist early 
on in treatment. Higher A2A levels may act to keep the brain in a primed state. 
 
Increased A2A receptor mRNA expression has been demonstrated in the striatum of 6-
OHDA lesioned rats and in MPTP-treated primates, as well as in dyskinetic PD patients 
chronically treated with levodopa64. They would also suggest that A2A blockade could be a 
useful pharmacological target for non-dopaminergic treatment of Parkinson’s disease with 
dyskinesia. A2A receptor antagonism has been shown to reduce dyskinesia in rodent lesion 
models of PD and relieves Parkinsonian motor deficits in non-human primate models of PD. 
For example, the A2A receptor antagonist KW-6002 resulted in improved control of the 
motor symptoms of PD when used as an adjunct with levodopa but did not reduce 
accompanying dyskinesias65.  However, no attempt to reduce levodopa dosage was made in 
this study. The use of an A2A blocker could potentially allow this and so be of benefit to PD 
patients. By preventing the priming of the brain, it may also be that early use of an A2A 
antagonist before the occurrence of dyskinesias would prevent or delay their evolution. 
 
In summary, the influence of the A2A receptor on basal ganglia functioning is complex 
involving regulation of D2 activity. Through its influence on activity in the indirect pathway the 
A2A site contributes to the development and maintenance of both parkinsonism and LID and 
so blockade could provide a non-dopaminergic treatment in Parkinson’s disease and 
possibly LID. 
 
I will now move to the individual studies done in an attempt to address the issues and 
questions raised in this introduction. 
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1.8 Figures 
 
Figure 1.1. Annihilation event produced with a positron being ejected from the nucleus. The 
positron travels a finite distance and annihilates by combining with an electron releasing two 
511keV gamma rays at 180º 2(p.50). 
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Figure 1.2. Possible coincidence events detected by a full ring PET scanner. The black circle 
indicates the site of positron annihilation. A – True event, B – Scattered event where 
electromagnetic radiation ejection does not occur at 180o, C – Random event for which 
correction can be applied and D – Multiple events resulting in 3 events being counted2(p.70). 
 
 
 
 
 
B A  
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Figure 1.3. Summery for the pre-preparation steps of PET analysis. 1. Creation of the Add 
Image, 2. Segmentation of the MRI and 3. Creation of the registered and labeled atlas. This 
atlas can then be used in region of interest analysis.   
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Figure 1.4 Summery of Statistical Parametric Mapping analysis. All subject scans are 
normalized into standard stereotaxic MNI space and smoothed. Scans are then grouped 
together and voxel clusters are compared statically. 
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Figure 1.7. A, β fibril formation, native protein arranges into β strands or sheets and then to 
protofibrils. Protofibrils then become arranged into fibrils binding Congo red. B, X-ray 
diffraction pattern of fibrillar amyloid. The 4.8Ᾰ meridonal arc measures the distance 
between β stands while 10-11 Ᾰ is due to spacing between β sheets38 (p.3,8). 
 
Figure 1.5. i. Illustration of a 
typical β strand. Strands become 
arranged by hydrogen bonds 
(dashed lines) to from ii and iii β 
sheets. Sheet ii arranged in a 
parallel strands while sheet iii 
arranged with anti-parallel 
strands36 (p.4).  
Native protein                   β stand/sheet              Protofilament                Protofibril                                Fibril 
A 
B 
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Figure 1.5. Schematic view of the membrane spanning and cleavage sites of APP770. The 
Aβ1–40 fragment and Aβ1–42 is generated by β and Ȣ cleavage. The p3 fragment, generated by 
α and Ȣ cleavage spans residues 688–711 and 71337 (p.7). 
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Figure 1.8. Schematic diagram of the indirect pathway of the basal ganglia. Black arrows 
illustrate inhibitory pathways while red arrows illustrate excitatory pathways. Gpe – globus 
pallidus externa, STN – subthalamic nuclei, Gpi/SNr – globus pallidus interna/substantia 
nigra reticulata. Of importance is the presence of a collateral system feeding back on the 
striatum. A2A receptors are represented along this pathway playing an important role on 
thalamic and cortical activity. 
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2.1 Microglial activation after Traumatic Brain Injury  
Investigations into TBI form a major part of this thesis. Previously thought to be a single 
event it is now apparent that TBI can lead to complications years after initial recovery. Here I 
will investigate if sustained microglial activation takes place in TBI at least 11 months after 
the event.  
  
Summary of Objectives 
Patient outcomes after TBI is highly variable. The underlying pathophysiology of this is 
poorly understood, but the inflammatory response is potentially an important factor. Microglia 
orchestrate many aspects of this response. Their activation can be studied in vivo using the 
PET ligand [11C]-PK11195. Here I investigate whether a persistent inflammatory response is 
present following chronic TBI, and whether this response relates to structural brain 
abnormalities and cognitive function. 
 
Ten patients at least 11 months post moderate to severe TBI, underwent [11C]-PK11195 
and structural MRI, including diffusion tensor imaging to assess white matter structure. 
[11C]-PK11195 binding potentials were calculated in and around the site of focal brain 
damage, and in distant brain regions affected by TBI. Standardised neuropsychological tests 
were administered. 
 
Summary of results 
[11C]-PK11195 binding was significantly raised in the thalami, putamen, occipital cortices, 
and the posterior limb of the internal capsules after TBI. There was no increase in [11C]-
PK11195 binding at the original site of focal brain injury. Higher [11C]-PK11195 binding in 
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the thalamus was associated with more severe cognitive impairment, although binding was 
not correlated with either the time since the injury or the amount of structural brain injury.  
 
In conclusion increased microglial activation is present up to seventeen years after TBI. 
Results suggest that TBI triggers a chronic inflammatory response in sub-cortical regions. 
This highlights the importance of considering the response to TBI as one that evolves over 
time and suggests intervention may be possible at times much later than previously thought. 
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2.2 Introduction 
The underlying pathophysiology of TBI remains poorly understood1. Patient outcomes are 
highly variable2 for reasons that are often unclear. Although TBI is often thought to involve a 
single event, resulting in a static pathological insult, new clinical effects can emerge many 
years after the injury. Patients can clinically improve or deteriorate years after TBI2 and may 
develop unexpected consequences such as post-traumatic epilepsy3 or late cognitive 
decline including AD4. In fact TBI is the most common acquired risk factor for AD. These 
observations suggest the presence of a dynamic element to the underlying pathophysiology 
of TBI. 
 
An important factor is likely to be the inflammatory response linked to TBI5,6,7. The initial 
insult results in neuronal injury, which can locally disrupt the blood brain barrier. Microglial 
cells resident in the CNS react to this injury within minutes, becoming chronically activated8,9. 
Once transformed, microglia become indistinguishable from peripheral macrophages, 
secreting cytokines and acting as antigen presenting cells10. In animal models, the initial 
inflammatory process has been shown to persist for at least a year5,7,11. In humans, post-
mortem studies have shown microglial activation many years after TBI12. Sites of activation 
often coincide with those of neuronal degeneration, and are seen particularly frequently in 
regions of axonal abnormality6,13. 
 
The inflammatory response to brain injury can be studied in vivo using the PET ligand [11C]-
PK1119514,15. [11C]-PK11195 binds to the translocator protein (TSPO), formerly known as 
the peripheral benzodiazepine receptor, expressed by the mitochondria of activated 
microglia16. Following stroke, microglial activation is observed early at the site of the infarct, 
as well as in  areas such as the thalamus and brainstem that become disconnected from the 
lesion14,15. Here I employ [11C]-PK11195 to study the inflammatory response following TBI. I 
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selected a group of patients in the chronic phase after TBI to test whether a persistent 
inflammatory response is present in injuries of varying severity. I then investigated whether 
microglial activation is related to MRI measures of disease severity including brain atrophy 
and changes in white matter signal. I also investigated the relationship between microglial 
activation and cognitive impairment, and tested whether persistent microglial activation is 
associated with more pronounced cognitive impairment. 
 
2.3 Methods 
2.3.1 Patients: demographic and clinical details 
Eleven patients with a history of TBI were recruited, and ten included in the analysis (mean 
age ± st.dev. 43±5.3, range 36–54, and mean time since injury ± st.dev. 6.2±5.3 years, 
range 0.9-17 years). One subject was excluded from the analysis because a history of 
alcohol dependency became apparent after scanning. All subjects had attained at least a 
secondary school level of education. Exclusion criteria were as follows: neurosurgery, except 
for invasive intracranial pressure monitoring; a history of psychiatric or neurological illness 
prior to the head injury; a history of previous significant TBI; anti-epileptic medication; 
pregnancy or breast feeding; current or previous drug or alcohol abuse; contraindication to 
MRI.  
 
Of the remaining ten TBI subjects, a road traffic accident was responsible for TBI in 6 cases, 
assaults in 3 cases, and in one case the cause was uncertain. All had suffered moderate to 
severe traumatic brain injuries based on the Mayo Clinic criteria17. To investigate whether 
persistent microglial activation was present, patients were all recruited in the chronic period 
after their injury (see table 2.1). Conventional neuroimaging was reviewed by a senior 
neuroradiologist. Five patients had no abnormalities visible on T1 MRI. The remaining five 
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had significant focal lesions with damage seen mostly in the frontal (n = 4) or temporal n = 3) 
lobes (see figure 2.1). Two patients had evidence of microbleeds on gradient echo imaging. 
Atrophy, contusion, gliosis and siderosis at the injury site were the most common changes 
described. One patient had undergone a frontoparietal lobectomy following TBI. All patients 
and control subjects gave written informed consent. The project was approved by 
Hammersmith and Queen Charlotte’s and Chelsea Research ethics committee. 
 
2.3.2 Control groups 
Two non-overlapping groups of control subjects were used in this study. Controls were 
chosen from the adult population and they underwent clinical and neuropsychological 
assessments to ensure that there were no underlying neurological illnesses. Seven age-
matched controls underwent [11C]-11195PK PET scanning and volumetric MRI scanning 
(mean age 46±4.0, range 42–50). Fifteen age-matched subjects underwent the 
neuropsychological assessment (mean age 37.3±11.3 range 19-60), and of those ten age-
matched control subjects had diffusion tensor imaging (mean age 40±10.9 range 19–60).  
 
2.3.3 Neuropsychological Assessment 
The following is a full description of the neuropsychological assessments subjects 
underwent. Essentially assessments were to include aspects of executive function and 
planning known to be adversely affected after TBI. 
 
Ten TBI patients (9 males, mean age ± standard deviation: 43.3 ± 5.3 years) and 15 age-
matched healthy controls (12 males, 37.3 ± 11.3 years) were compared on 
neuropsychological functioning. The assessment of the TBI patients was divided into two 
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one-hour sessions. The average time between the sessions was one week. The healthy 
volunteers were assessed during a single session of approximately an hour and a half. The 
battery of tests used was designed to focus on the assessment of executive functions, 
information processing speed and verbal memory, tapping domains of cognitive function 
often impaired following TBI. The Verbal Fluency/Letter Fluency (F + A +S) and Color-Word 
subtests from the Delis-Kaplan Executive Function System (D-KEFS) were administered to 
assess word generation fluency, complex information processing speed, inhibition and 
cognitive flexibility. The Trail Making Test (TMT) was used to assess basic perceptual and 
complex processing speed, attentional capacity, set-maintenance and set-shifting. A 
computerised two-choice left/right button-press choice-reaction task (CRT) was used as a 
simple processing speed measure (median reaction time on correct trials). The TMT Form A, 
as well as the two baseline conditions of the D-KEFS Color-Word interference test, Color 
Naming and Word Reading also measured simple processing speed. The Digit Span subtest 
of the Wechsler Memory Scale- Third Edition (WMS-III) assessed initial and working 
memory. The Logical Memory I and II subtests of the WMS-III were used as a measure of 
immediate and delayed verbal recall. The People Test (PT) from the Doors and People Test 
battery was used as a measure of associative learning and recall (immediate recall). In 
addition, the Wechsler Test of Adult Reading (WTAR) was used to provide an estimate of 
pre-morbid intellectual functioning. Current verbal and nonverbal reasoning ability were 
assessed via the Wechsler Abbreviated Scale of Intelligence (WASI) Similarities and Matrix 
Reasoning subtests. Individual differences in current intellectual ability were taken into 
account when calculating the group averages for the other indices of cognitive function by 
comparing the groups on standardised residuals after regressing out intellectual ability. 
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2.3.4 Volumetric and diffusion tensor MRI 
Standard protocols were used for high resolution T1, gradient-echo (T2*) and diffusion 
tensor imaging (DTI) to assess the extent of focal brain injury and white matter disruption. 
Fractional anisotropy (FA) and mean diffusivity (MD) were calculated in three regions of 
interest within the corpus callosum, as well as the anterior and posterior internal capsule. 
These regions are frequently disrupted by diffuse axonal injury, and were used to provide a 
representative measure of white matter tract damage after TBI18,19. 
 
MRI data were obtained using a Philips (Best, The Netherlands) Intera 3.0 Tesla MRI 
scanner using Nova Dual gradients, a phased array head coil, and sensitivity encoding 
(SENSE) with an under-sampling factor of 2. The T1 and T2*-weighted images were 
obtained prior to DTI. For DTI, diffusion-weighted volumes with gradients applied in 16 non-
collinear directions were collected in each of the four DTI runs, resulting in a total of 64 
directions. The following parameters were used: 73 contiguous slices, slice thickness = 2 
mm, field of view (FOV) 224 mm, matrix 128 x 128 (voxel size = 1.75 x 1.75 x 2 mm3), b 
value = 1000, and four images with no diffusion weighting (b = 0 s/mm2).  
 
2.3.5 Diffusion tensor imaging analysis 
Diffusion-weighted images were registered to the b = 0 image by affine transformations to 
minimize distortion due to motion and eddy currents, and then brain-extracted using BET, a 
part of the FSL image processing toolbox. Fractional anisotropy (FA) and mean diffusivity 
(MD) maps were generated using the FSL’s Diffusion Toolbox. A region of interest approach 
was taken, focusing on white matter tracts commonly affected by TBI, namely the anterior 
and posterior limbs of the internal capsule, and the corpus callosum. These regions were 
hand drawn or manually checked using individual high resolution T1 MRI images, voxel size 
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1x1x1mm. These regions were hand drawn or manually checked using individual high 
resolution T1 segmented MRI images (voxel size 1x1x1mm), and the masks then 
thresholded and binarised. The resultant case specific masks were translated into diffusion 
space using FSL’s Linear Image Registration Tool with nearest neighbour registration and 
re-thresholded. The mean FA and MD values were then extracted for each ROI. 
 
2.3.6 PET image acquisition and analysis 
PET scanning was performed using established protocols at the Cyclotron Building, 
Hammersmith Hospital, London, UK, with a Siemens ECAT 962 EXACT HR+ scanner. The 
Siemens ECAT 962 EXACT HR+ scanner has an axial view of 15.5 cm. Prior to scanning, 
intravenous access was secured in the antecubital fossa of each subject. A 10 minute 
transmission scan was acquired before the emission study, using a single rotating photon 
point source of 137Cs, for subsequent attenuation and scatter correction. The resultant 
dynamic PET consisted of 18 time frames covering all 60 minutes. The PET data, were 
acquired in 3-dimensional mode. Data were reconstructed using filtered back projection to 
produce images containing 63 contiguous slices, separated by 2.42mm, of 128x128 pixels 
2.092mm square. Reconstruction of emission data was carried out using filtered back 
projection. The 3D emission data were Fourier-rebinned into 2D data sets to increase the 
speed of reconstruction. The reconstructed image had a transaxial resolution of 6.5 mm. 
Thirty seconds after the start of emission scanning a mean dose of 370.9 MBq [11C]-
PK11195 was administered intravenously over 10 seconds into the antecubital vein of each 
subject. This was followed by a 60 minute dynamic emission PET scan acquired as 18 time 
frames.  
 
The ligand [11C]-PK11195 binds to the translocator protein (TSPO) expressed by activated 
microglial cells. The widespread expression of this protein after TBI makes it difficult to 
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select a reference region representing non-specific [11C]-PK11195 uptake. For this reason, I 
used a supervised clustering procedure for [11C]-PK11195 analysis20. Parametric images of 
[11C]-PK11195 binding potential (BP), reflecting Bmax/Kd, were generated with a simplified 
tissue reference model (SRTM). No assumptions were made about the distribution of 
activated microglia in TBI subjects. For each scan, cluster analysis was employed to identify 
and extract clusters of voxels where [11C]-PK11195 binding is similar to a normal population 
cortical reference input function. This process is carried out by the automated computational 
program SUPERPK (Imperial Innovations, Imperial College London) written in Matlab (The 
Mathworks Inc., Natick MA) 20. This program compares the time activity curves (TAC) of 
each pixel with the kinetics of six pre-defined tissue types (normal gray and normal white 
matter, skull, muscle, gray matter with reactive microglia, endothelial cells rich in the TSPO 
receptor and smooth muscles) obtained from a database of control subjects and patients. 
BP’s were computed for clusters where tracer retention occurred by comparison with the 
TAC of the defined reference grey matter cluster. In cluster analysis, these clusters are used 
as the reference region for creation of the parametric image.  
 
2.3.7 Brain segmentation and region of interest definition 
A number of anatomically predefined regions of interests (ROIs) were selected to sample 
[11C]-PK11195 binding. The MAPER (multi-atlas propagation with enhanced registration) 
procedure was used to generate anatomical ROIs from the subject's MRI brain image in its 
native space. The procedure has previously been shown to yield accurate and robust 
segmentations in normal subjects as well as those with dementia21,22. This approach 
minimised the potential sampling error associated with mis-registration and brain atrophy. 
The output of automatic segmentation was reviewed visually. Five patients focal brain injury 
was visible on T1-weighted MRI (see figure 2.1). Where damage fell within an ROI, the ROI 
was removed from the analysis, as correct anatomical segmentation of the injured region 
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was not always possible. In five of the ten patients, manual modifications were made to the 
segmentations before further processing. The volume of the segmented regions was used to 
investigate whether [11C]-PK11195 binding was associated with brain atrophy following TBI. 
Regions were chosen to provide a representative sampling of cortical, sub-cortical and white 
matter structures, and included a number of regions likely to be affected by TBI. The 
following regions were sampled: the anterior and posterior cingulate cortices, inferior and 
superior frontal gyri, hippocampi, occipital lobes, cerebellum, caudate, putamen, brain stem 
and thalamic nuclei, and the corpus callosum, as well as the anterior and posterior limbs of 
the internal capsule.  
 
In the five patients with focal brain injury (see figure 2.1) I investigated whether [11C]-
PK11195 binding was increased within or near the site of this injury. I defined cylinder-
shaped ROIs 10 mm long with a 5mm radius in and around the most prominent lesion. One 
ROI was placed centrally within the lesion. This ROI thus sampled the lesion itself and its 
borders were not allowed to extend into peri-lesional areas as defined by the T1 weighted 
MRI. A second ROI was placed within the tissue adjacent to the lesion that returned 
abnormal T1 signal. Again care was taken to ensure that the ROI borders did not extend into 
areas of different signal change but rather sampled abnormal peri-lesional tissue. Cylinders 
were orientated parallel to the long axis of the lesion. A further two ROIs were placed in grey 
and white matter returning normal MR signal in the same lobe as the lesion sampled. This 
enabled [11C]-PK11195 binding to be investigated within the lesion, the lesion penumbra, 
and the normal grey and white matter of the same lobe. 
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2.4 Results 
2.4.1 Cognitive performance 
Our TBI patients showed slowed information processing in line with previous reports.23 
Significantly prolonged processing times were seen across a range of cognitive tasks of 
varying complexity (see table 2.2). In other ways the patients were matched 
neuropsychologically with controls. One patient could not be fully assessed because of 
upper limb disability and difficulty communicating verbally. 
 
2.4.2 TBI patients show increases in microglial activation remote from damaged areas 
Patient [11C]-PK11195 binding potentials were significantly higher than controls in a number 
of brain regions distant from any focal damage. Initial analysis showed no significant 
hemispheric differences in binding potentials (P>0.3 for all paired Student’s t-test inter-
hemispheric comparisons). Therefore, [11C]-PK11195 binding potentials for paired 
structures are reported as an average of binding in the two hemispheres where this is 
appropriate. Using the generalised linear model, ANOVA showed a significant group by 
region interaction (F(1,13) = 1.09, p=0.033), resulting from higher patient [11C]-PK11195 
binding in the thalami (t=4.443, df=15, p<0.001), putamen (t=3.63, df=15, p=0.002), occipital 
lobes (t=2.75, df=15, p=0.015), and within the posterior limb of the internal capsules (t=2.67, 
df=15, p=0.017). Non-parametric testing with Mann-Whitney U Tests confirmed these 
results. Thalamic [11C]-PK11195 binding potentials remained significantly elevated 
compared to controls after Bonferroni correction for multiple comparisons. 
 
There was no significance between the time interval since head trauma and [11C]-PK11195 
binding (P>0.2). The highest [11C]-PK11195 binding was actually observed in the patient 
whose injury was most remote in time (see figure 2.2). [11C]-PK11195 binding did not 
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correlate with structural measures of brain injury. In the four regions showing a significantly 
raised [11C]-PK11195 binding there was no correlation between tracer uptake and the 
volume of the regions (P>0.2 for all analyses). Additionally, there was no correlation 
between [11C]-PK11195 binding and the measures of white matter damage provided by DTI. 
TBI often produces diffuse axonal injury and this can be quantified as loss of white matter 
anisotropy (directionality of water flow) using DTI18,24. As expected, compared to a matched 
control group, patients showed evidence of white matter disruption. Fractional anisotropy 
was significantly lower and mean diffusivity higher in all three white matter regions in the 
patient group, except for FA measured in the anterior limb of the internal capsule. However, 
there was no significant correlation between [11C]-PK11195 binding and either of these 
metrics (P>0.2 for all analyses).  
 
2.4.3 Microglial activation is not increased around the sites of focal brain damage 
Visual inspection of the TBI patients [11C]-PK11195 images showed no obviously increased 
uptake in the vicinity of focal lesions evident on MRI (see figure 2.4). To confirm this 
quantitatively I measured [11C]-PK11195 binding in ROI’s placed in and around the most 
prominent focal lesion in each patient, where lesions were visible on T1–weighted MRI. 
[11C]-PK11195 binding was similar within the focal lesion and in the penumbral region. In 
contrast, [11C]-PK11195 uptake in both these regions was significantly lower than in the 
thalami (lesion t=-20.1, df=4, p<0.005, penumbra t=-25.8, df=4, p<0.005), as well as the 
normal appearing cortex (lesion t=-3.9, df=-22.4, p<0.005, penumbra t=-4.1, df=4, p=0.015) 
and white matter (lesion t=-3.9, df=4, p=0.017, penumbra t=-7.1, df=4, p=0.002) of the same 
hemisphere. 
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2.4.4 Increased thalamic microglial activation correlates with cognitive impairment 
 
In distant regions showing increased microglial activation following TBI, I next investigated 
whether levels of cognitive impairment correlated with [11C]-PK11195 binding. Higher 
thalamic [11C]-PK11195 uptake correlated inversely with the speed of processing complex 
information, as indexed by reaction times to conflicting items on the Stroop, a test of 
selective attention (Spearman r=0.828, p=0.006, see figure 2.5). This result remained 
significant after controlling for current IQ. There was also a correlation between thalamic 
binding and speed of naming the ink colour in the Stroop, a simpler part of the test, which 
reached borderline significance (Spearman r=0.650, p=0.058). The other three regions with 
increased [11C]-PK11195 binding did not show significant correlations with cognitive 
performance. 
 
2.5 Discussion 
TBI is often regarded as a single event causing static pathological damage. Using [11C]-
PK11195 PET I have been able to demonstrate in vivo that microglial activation persists 
many years after the initiating insult. This result builds on findings in animal models and in 
post-mortem human studies, which have also shown that TBI triggers a long-term 
inflammatory response5,6,12. Surprisingly, persistent microglial activation does not involve the 
original areas of focal brain injury, but rather, is most prominent within sub-cortical structures 
remote from the site of focal injury, particularly the thalami and putamen. This may reflect the 
dense connectivity of these structures. TBI often results in diffuse axonal injury that 
disconnects subcortical structures25 and microglia have been shown to be persistently 
activated at such sites helping to remodel connections5,6,14.  
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Patients show a highly variable clinical outcome following TBI, for reasons that are poorly 
understood2. Here I have shown that impaired cognitive function after TBI is associated with 
greater thalamic microglial activation. This suggests that persistent thalamic inflammation, 
possibly secondary to disconnection, is associated with cognitive outcome. My results 
emphasize that TBI should be viewed as a condition with a persistent inflammatory 
component and this may provide a novel target for therapeutic intervention. 
 
These results are consistent with pathological studies on microglial activation following TBI, 
and other cerebral insults14,16. Microglial activation is seen within the first few minutes of 
focal brain injury 8,9 and, as the inflammatory response develops, activated cells are seen in 
remote but connected white matter tracts. Two weeks after cortico-spinal tract infarction high 
[11C]-PK11195 binding is seen at the site of the stroke, accompanied by a lower increase in 
binding in remote but connected parts of the pyramidal tract14. The local and distant sites of 
inflammation may contain different populations of activated microglial cells showing different 
patterns of major histocompatibility complex expression11,26 and distinct time courses for 
their activation. Follow-up scanning 6 months after the stroke showed that remote microglial 
activation increases, while binding potentials at the site of the infarct revert to normal 
values14. My work corroborates these findings in TBI. Reduced levels of [11C]-PK11195 
binding at the sites of focal lesions demonstrate that microglial activation does not persist in 
these areas. This may be due to the astrocytic response to TBI enclosing and isolating the 
damaged area, thereby removing the source of microglial stimulation27. Alternatively, 
microglia may persist at the site of focal lesions but down-regulate expression of TSPO over 
time. 
 
After TBI, persistent microglial activation was particularly prominent in the thalami and 
putamen. This may be secondary to widespread white matter damage, due to the presence 
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of diffuse axonal injury. In animal models of TBI, on-going axonal damage is seen in the 
striatum and thalamus28, and activated microglia are present a year after trauma in white 
matter tracts connected to focal cortical injuries5,11. In humans, post-mortem studies show 
that activated microglia are present in both the thalami and brainstem many years after 
TBI6,13. Within the thalamus, the cells are mainly observed in white matter surrounding 
separate nuclei. Following motor stroke increased [11C]-PK11195 binding in parts of the 
pyramidal tract remote from the infarct has been shown to correlate with the extent of white 
matter damage14. As a group patients showed evidence of generalised white matter 
damage, consistent with the presence of diffuse axonal injury18,24. However, the location of 
increased [11C]-PK11195 binding did not correlate with the white matter structural change 
detected by DTI, perhaps because the latter is influenced by directionality of water diffusion 
along fibres rather than the cellular reaction to fibre loss. It must be remembered however 
that only 3 white matter regions were sampled in this study. It may be that further sampling is 
necessary to identify areas were DTI makers and [11C]-PK11195 uptake do correlate.  
 
The clinical significance of persistent microglial activation remains uncertain. Microglia play 
an important role in the immune response, releasing cytokines, acting as antigen presenting 
cells and clearing debris in the acute phase after brain injury10. The initial benefits of debris 
clearing and synaptic remodelling may be countered by subsequent damaging effects when 
microglial activation is prolonged and accompanied by excessive and poorly regulated 
release of cytokines12. Activated microglia can be cytotoxic 29 and their persistent activation 
might predispose to the development of neurodegenerative conditions such as AD in 
susceptible individuals, or provide the context in which such diseases take a more 
aggressive course12,30. In contrast, recent work suggests that persistent microglial activation 
in regions remote from focal injury might promote brain repair5,11,14. Firstly, in humans, 
microglial activation in the pyramidal tract remote from a motor stroke was correlated with a 
positive clinical outcome14. In non-human primates, microglia continue to release brain-
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derived neurotrophic factor (BDNF) many months after an injury, whilst the production of 
other cytokines associated with the acute inflammatory reaction is stopped5. The release of 
BDNF is associated with local synaptogenesis, which suggests that activated microglia might 
play a role in regulating brain repair after TBI5,11. 
 
My results also reveal a relationship between the amount of microglial activation in the 
thalamus and cognitive function. Patients with higher [11C]-PK11195 binding within the 
thalamus showed impaired information processing speed, a common problem after TBI. 
Cognitive impairment after TBI results in part from the disconnection of distributed brain 
networks. This is likely to be particularly important for the speed and efficiency with which 
cognitive functions can be performed. As the thalamus is a key node in most distributed 
networks, abnormalities within this structure are likely to have a profound influence. TBI is 
known to produce damage within the thalamic nuclei particularly involved with cognitive 
functions6, and observation that microglial activation is localised to the thalamus many years 
after TBI suggests that an on-going inflammatory response within the structure may be 
relevant to the cognitive impairment that persists after TBI. Persistent microglial activation in 
the thalamus may drive adaptive changes in synaptic plasticity, which are most prominent in 
patients with severe thalamic damage. Alternatively, microglial activation could directly 
contribute to chronic damage of the thalamus, which impairs its function.  A cross-sectional 
design, such as I employed, does not help to resolve this dilemma. Longitudinal clinical 
studies using [11C]-PK11195 will be necessary to determine the functional significance of 
thalamic microglial activation. Of interest as well would be the employment of thalamic maps 
to help differentiate regional areas of increased uptake within the thalamus itself. This was 
however beyond the scope of this study. 
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The observation that microglia are persistently activated emphasizes that TBI should not be 
viewed as a static insult, but instead as a trigger for a complex cascade of events that 
includes a persistent inflammatory state. This suggests that the window of opportunity for 
therapeutic intervention following TBI may be much longer than is usually considered. In vivo 
[11C]-PK11195 imaging provides a biomarker to investigate this inflammatory state, and can 
be used to study the time course of inflammation after TBI and the effects of interventions 
aimed at manipulating the inflammatory cascade. 
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2.6 Tables 
Table 2.1. Demographics and clinical data of all traumatic brain injury (TBI) patients 
AGE SEX HIGHEST 
LEVEL OF 
EDUCATION 
CAUSE OF 
TBI 
LOWEST 
GCS 
RECORD
ED 
POST_ 
TRAUMAT
IC 
AMNESIA 
(hrs) 
CURRENT 
MEDICATION 
INTERVAL 
SINCE 
TRAUMA 
(months) 
45 M Postgraduate Unknown 4 24 Gabapentin 
Modafenil 
Amitriptyline 
72 
 
55 M Postgraduate Fall 
 
4 UK nil 36 
42 M School to 18 Pedestrian 
hit by a car 
 
4 432 nil 72 
36 M Postgraduate Cycling 
accident 
 
6 24 nil 24 
42 M School to 16 Motorcycle 
accident 
 
4 UK Tropium 
chloride 
Folic acid  
204 
40 M Graduate 
degree 
Motorcycle 
accident 
 
4 1008 nil 132 
42 F Postgraduate  Pedestrian 
hit by a car 
 
3 144 Codine 
Paracetamol  
72 
45 M School to 16 
 
Assault 4 5040 Thiamine 11 
49 M School to 18 Probable 
assault 
 
4 2 nil 11 
38 M Graduate Motorcycle 
accident 
 
6 UK Citalopram 
Modafanil 
Omeprazole 
108 
UK – unknown  
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Table 2.2 Neuropsychological test results: traumatic brain injury and control patients. 
COGNITIVE DOMAIN COGNITIVE VARIABLE TBI 
Mean±SD
 a) 
CONTROL 
Mean±SD
 a) 
TBI vs.  
CONTROL 
b) 
 Intellectual ability:             Reading  
Verbal 
Non-verbal 
WTAR age-scaled score 
WASI Similarities 
WASI Matrix Reasoning 
107±10.1 (N=9) 
39.4±3.7 (N=9) 
28.1±3.5 (N=10) 
112±9.8 (N=15) 
34.5±6.3 (N=15) 
26.8±5.0 (N=15) 
t = − 1.10 
ns
 
t = 2.45 * 
t = 0.71 
ns
 
Executive function:          Inhibition 
Cognitive flexibility 
 
Word generation fluency 
                              Set-shifting 
Inhibition – naming (s) 
Inhibition/switching – 
naming + reading ÷ 2 (s) 
Letter Fluency F+A+S 
total 
Alternating-switch cost : 
TMT Trails B minus A (s) 
31.8±22.4 (N=9) 
46.7±27.9 (N=9) 
 
40.4±4.8 (N=9) 
 
 
25.6±17.8 (N=10) 
28.7±17.6  (N=15) 
32.2±10.5 (N=14) 
 
46.0±12.0 (N=15) 
 
 
23.3±9.8 (N=14) 
t = 0.23 
ns
 
t = 1.39 
ns
  
 
t = 0.36 
ns
  
 
 
t= 0.57 
ns
 
Processing time:   Visual search 
                                        Complex 
                                          Naming 
                                         Reading 
                                        Complex  
                      Choice reaction time 
TMT Trail A (s) 
TMT Trails B (s) 
Colour Naming (s) 
Word Reading (s) 
Inhibition (s) 
CRT median RT (ms) 
31.7±15.0 (N=10) 
57.3±28.6 (N=10) 
37.9±12.0 (N=9) 
26.3±6.3 (N=9) 
69.7±30.7 (N=9) 
456±62 (N=9) 
19.7±4.5 (N=14) 
43.0±12.6 (N=14) 
33.2±.4.0 (N=14) 
28.9±6.3 (N=15) 
23.3±4.4 (N=15) 
408±51 (N=15) 
t = 2.06 
ns
 
t = 1.16 
ns
 
t = 3.15 ** 
t = − 0.53 
ns
 
t = 4.50 ** 
t = 2.16 * 
Memory:         Immediate/Working 
                                  
                                           Logical 
                           
 
 
                                    Associative 
Digit Span forward 
Digit Span backward 
WMS-III LM I first recall 
total 
WMS-III LM I total 
WMS-III LM II delayed 
PT immediate recall total 
 
10.5±1.5 (N=10) 
7.2±1.4 (N=10) 
 
28.4±3.7 (N=9) 
47.1±5.4 (N=9) 
31.9±5.1 (N=9) 
26.0±5.7 (N=10) 
11.5±2.2 (N=15) 
7.5±2.0 (N=15) 
26.4±9.0 (N=15) 
42.7±13.7 (N=15) 
25.6±9.2 (N=15) 
26.9±7.1 (N=15) 
t = − 1.28 
ns
 
t = − 0.66 
ns 
t = 0.02 
ns
 
t = 0.17 
ns
 
t = 0.99 
ns
 
t = − 1.03 
ns
 
 
Neuropsychological results for TBI patient and age-matched control group. a) Following 
exploratory data analysis control subjects identified as extreme outliers (≥ 3 x interquartile 
range) were excluded. b) Significant group differences shown by *P ≤ 0.05 and **P ≤ 0.01; 
ns indicates a not significant result. Group contrasts are made controlling for differences in 
current intellectual ability. WTAR = Wechsler Test of Adult Reading. WASI = Wechsler 
Abbreviated Scale of Intelligence; Inhibition, Inhibition/Switching, Letter Fluency, Colour 
Naming, and Word Reading subtests are from the Delis-Kaplan Executive Function 
System Color-Word Interference Test; TMT = Trail Making Test; CRT = Choice-Reaction 
Task; WMS-III = Wechsler Memory Scale- Third Edition; PT = People Test. 
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2.7 Figures 
 
Figure 2.1. Transverse sections through T1 weighted MRI, in traumatic brain injury (TBI) 
patients (n=5) with focal brain lesions. R=right. 
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Figure 2.2. Chronic microglial activation is present following TBI. Overlay images of the 
transverse T1 MRI at the level of the thalamus superimposed with [11C]-PK11195 binding 
potential images of all traumatic brain injury (TBI) subjects and a representative control 
subject. Numbers indicate time in months from the time of TBI to PET scanning. Images 
illustrate the greater binding of [11C]-PK11195 in the thalami of all TBI subjects. R = right. 
 
 
Figure 2.3. [11C]-PK11195 binding in the regions of interests investigated. Error bars, 95% 
confidence interval. Individual subjects binding potentials are plotted with patients in blue 
and control subjects in red. AC – anterior cingulate, PC – posterior cingulate, Caud – 
caudate, Puta – putamen, Thal – thalami, Hippo – hippocampus, OL – occipital lobe, IFG – 
inferior frontal gyrus,    SFG – superior frontal gyrus, Cere – cerebellum, PIC – posterior limb 
of internal capsule, AIC – anterior limb of internal capsule, BS – brainstem and CC – corpus 
callosum. *p<0.05 significance, **survives Bonferroni multiple comparison correction. 
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Figure 2.4. Microglia are not chronically activated around the site of focal brain damage 
following TBI. [11C]-PK11195 binding potentials (BP) in representative regions drawn at the 
lesion site, in the penumbral region of the lesion, and within normal appearing grey and 
white matter in the same hemisphere. Thalamic binding values correspond to the mean BP 
of the right and left thalami. Results demonstrate no abnormal increase in [11C]-PK11195 
binding in or around the lesion site. GM = grey matter, WM = white matter. 
 
 
 
 
Figure 2.5. Thalamic microglial activation correlates with complex information processing 
speed. [11C]-PK11195 binding in bilateral thalamic regions plotted against speed of 
responding to incongruent items on the Color-Word Interference Test Inhibition trial providing 
a measure of complex information processing speed. 
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Chapter 3 
 
Amyloid plaque disposition after Traumatic 
Brain Injury 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
85 
 
3.1 Amyloid plaque disposition after Traumatic Brain Injury 
Chronic TBI is a hyperinflammatory state. In this chapter eight of the TBI subjects 
investigated with [11C]-PK11195 form the previous chapter went on to have further PET 
scanning with [11C]-PIB in an attempt to detect amyloid plaque deposition.  
 
Summary of Objectives 
Patients surviving TBI have at least twice the normal risk of developing late onset AD. The 
underlying pathophysiology of this is poorly understood, but the early deposition of fibrillar 
amyloid is potentially an important factor. The load of fibrillar amyloid can be determined in 
vivo using the PET ligand [11C]-PIB. In this study I investigate whether fibrillar amyloid can 
be identified in chronic TBI patients. 
 
Eight patients were studied at least 11 months after moderate to severe TBI. All underwent 
[11C]-PIB PET and structural MRI (including diffusion tensor imaging). Standardised uptake 
values (SUV’s) of [11C]-PIB were calculated for all TBI subjects as well as 10 normal control 
subjects previously scanned at the department.  The SUV’s in anatomically defined regions 
known to be involved in AD and TBI were investigated and compared. Standardised 
neuropsychological tests were administered. 
 
Summary of results 
There was no significant difference in regional brain SUV’s between TBI subjects and normal 
controls. This was despite differences identified in neuropsychological assessment where 
the TBI group demonstrated poorer functioning with complex reasoning.   
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The results demonstrate absence of a significant fibrillar amyloid load in chronic TBI 
patients. The negative PET findings, however, do not exclude the presence of raised soluble 
or amorphous forms of amyloid as [11C]-PIB does not label these compounds. These results 
were evident despite neuropsychological deficits in the TBI group.  
 
These findings should be considered preliminary and the longitudinal investigation of 
subjects will be necessary to demonstrate eventual amyloid plaque formation. Results 
suggest, however, that fibrillar amyloid is not directly related to cognitive impairment.  
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3.2 Introduction 
TBI is a major socioeconomic burden and a significant cause of mortality and morbidity in 
the younger age group1. Patient outcome is highly variable and even after an initial good 
recovery; many survivors still have some degree of residual cognitive impairment. This can 
worsen over time and there is compelling evidence that survivors of TBI are at a higher risk 
for the development of AD later on in life 2. 
 
TBI sets off a sequence of events resulting from damage to the blood brain barrier. Within 
hours there is an intense inflammatory response accompanied by microglia activation and 
increased expression of the APP and soluble amyloid 3. TBI should however not be 
considered a static event and activated microglia have been identified in animals at least a 
year after the initial event and several years after the initial event in human post mortem 
studies. I previously reported on sustained microglial activation in the thalami of TBI subjects 
up to 17 years after their initial event. Accompanying this inflammatory response is an 
increased β amyloid protein deposition2. This has also been reported in 30% of subjects 
dying within 4 hour to 2.5 years after severe TBI 4. β amyloid plaque formation and 
deposition is a pathogonomic marker of AD and is thought to contribute to cortical damage. It 
is unclear however how amyloid pathology relates to the future development of cognitive 
impairment in TBI.  
 
It is now possible with PET to identify fibrillar β amyloid plaque deposition in vivo using the 
radioactively labelled tracer Pittsburgh compound B (PIB). This thioflavin analogue binds to a 
non-physiological site between the planar folds of the β pleated sheets making up the 
amyloid plaque5,6.  It has been used in many studies to label and quantify amyloid load in 
many conditions including AD, mild cognitive impairment (MCI) and healthy elderly 
controls7,8. Two fold higher levels are found in AD, while 60% of MCI show increased uptake. 
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It should be noted however that up to 50% of healthy elderly controls in their 8 th decade have 
increased [11C]-PIB uptake 9,10.  
 
In this study I make use of [11C]-PIB PET to investigate patients with chronic head injury 
and hypothesise that these subjects will show cortical β amyloid plaque deposition. A wide 
range of subjects including those with residual mental and physical disability were included 
as well as those who had returned to their normal level of premorbid functioning. I 
hypothesised that amyloid plaque deposition would be higher in chronic TBI subjects with 
cognitive impairment.  
3.3 Methods 
Eight subjects were recruited from local head injury clinics in the UK, mean age 44.0±5.2 
years. All subjects suffered from a moderate to severe head injury based on the Mayo 
Criteria at least 11 months before investigation. As before, exclusion criteria were as follows: 
neurosurgery, except for invasive intracranial pressure monitoring; a history of psychiatric or 
neurological illness prior to the head injury; a history of previous significant TBI; anti-epileptic 
medication; pregnancy or breast feeding; current or previous drug or alcohol abuse; 
contraindication to MRI.  Neurosurgery at the time of TBI and the presence of intra-cerebral 
lesions were not exclusion criteria. Subjects needed to be able to undergo MRI scanning.  
Significant vascular pathology on T2 MRI was an exclusion criterion. See table 3.1 for the 
clinical details of the subjects investigated.  
 
Structural neuroimaging was reviewed by a senior neuroradiologist. Three patients had no 
abnormalities visible on T1 MRI. The remaining five had significant focal lesions with 
damage seen mostly in the frontal (n = 4) or temporal (n = 3) lobes (see figure 3.1). Two 
patients had evidence of microbleeds on gradient echo imaging. Atrophy, contusion, gliosis 
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and siderosis at the injury site were the most common changes described. All patients gave 
written informed consent. The project was approved by Hammersmith and Queen 
Charlotte’s and Chelsea Research ethics committee. 
 
TBI subject scans were compared to 10 healthy control scans held on a database at 
Hammersmith Imanet. Controls were from the adult population and had underwent clinical 
and neuropsychological assessments to ensure that there were no underlying neurological 
illnesses. The control group formed part of a study on [11C]-PIB uptake in AD and hence 
were significantly older than the TBI group.  
 
3.3.1 PET image acquisition 
All subjects were scanned using a Siemens ECAT 962 EXACT HR+ scanner which has an 
axial view of 15.5 cm. Prior to scanning, an intravenous cannula was inserted in the 
antecubital fossa of each subject. A 10 minute transmission scan was acquired before the 
emission study, using a single rotating photon point source of 137Cs, for subsequent 
attenuation and scatter correction. The PET data were acquired in 3-dimensional mode. 
Data were reconstructed using filtered back projection to produce images containing 63 
contiguous slices, separated by 2.42mm, of 128x128 pixels 2.092mm square. 
Reconstruction of emission data was carried out using filtered back projection. The 3D 
emission data were Fourier-rebinned into 2D data sets to increase the speed of 
reconstruction. The reconstructed images consisted of sixty-three transaxial image planes 
were displayed as 2.46-mm slices with a reconstructed axial resolution of 5.4 mm and a 
transaxial resolution of 5.6 mm.  
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Following the transmission scan and 30 seconds after the start of the emission scan, all 
subjects received 367 16.4 MBq [11C]-PIB injected IV. This was followed by a 90 minute 
dynamic emission scan comprising 32 time frames. [11C]-PIB was manufactured by 
Hammersmith Imanet, GE Healthcare at the Cyclotron Building, Hammersmith Hospital.  
 
All image processing were performed using Analyze (Mayo Clinic, MN) and SPM2 
(Wellcome Department of Imaging Neuroscience, University College London, UK) running in 
MATLAB 5 (R12, Mathworks, Natick, MA).  
 
3.3.2 PET image analysis – Standardised Uptake Value  
Time frames corresponding to 10-90 minute (early and late) and 60-90 minute (late) 
summation images were created for each [11C]-PIB scan. Each subject’s MRI was then 
coregistered to its corresponding PET scan and segmented into grey matter, white matter 
and cerebrospinal fluid (CSF). An in house atlas was then normalized and convolved with 
the grey matter segmented image11.  Individualized cortical grey matter regions were thus 
defined. The atlas was first applied to the subjects’ MRI and visually checked to ensure the 
regions outlined were structurally correct. Manual alterations were made where appropriate. 
In the case of the five subjects with focal atrophy, regions which were distorted were again 
removed from analysis. It is noteworthy that in all case the contralateral region remained 
intact ensuring that all regions were represented in all subjects for analysis. Checked and 
modified atlases were then applied to the late [11C]-PIB scans. It should be noted that this 
late [11C]-PIB PET data was not modified in any way. 
 
For the quantitative analysis of [11C]-PIB scans the cerebellum is normally used as the 
reference region for non-specific binding. In AD this region is not affected by fibrillar deposits 
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of amyloid and hence has no specific binding of [11C]-PIB but rather provides a value for 
background [11C]-PIB uptake12,13. TBI however is a heterogeneous condition with 
widespread areas of focal damage and potential amyloid deposition. As  one cannot be 
certain that TBI would not provoke localised inflammation and amyloid deposition in the 
cerebellum I chose to calculate standardised uptake values (SUV) to quantitate regional 
brain [11C]-PIB binding.   This factor is calculated according to the subjects’ body surface 
area and the radioactivity injected. The formula below was employed: 
SUV (m2/MBq) = Late Add Image x (body surface area(m2)/Activity injected (MBq)). 
The late summated [11C]-PIB PET image was thus transformed to an SUV image. During 
this normalization process, region volumes are not changed or warped into standard space.  
 
The use of SUV in creating parametric [11C]-PIB data is less well established than the 
determination of cerebellar RATIO images. Its use however, enabled meaningful analysis for 
[11C]-PIB data in this study. Ideally blood data to generate an arterial input function enabling 
spectral analysis could have been attempted. However SUV ratio parametric images have 
been shown to be as dependable as spectral analysis using the Logan approach14. Arterial 
blood data was thus thought unnecessary and was not performed in this study. 
 
SUV’s were calculated for both TBI and control scans and anatomically defined regions of 
interest (ROI’s) were sampled. SUV’s of all ROI’s were compared using non-parametric 
Mann Whitney U test. Significance level was set as P=0.05. 
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3.3.3 Neuropsychological Assessment 
Neuropsychological assessments of the 8TBI patients having [11C]-PIB PET scans were 
extracted from the original 15 investigated in Chapter 2 and analysed independently. Further 
neuropsychology was not thought to be necessary specifically for this study.  
 
3.4 Results 
3.4.1 PET scanning 
For the regions sampled [11C]-PIB retention was not significantly higher in the TBI group 
compared to the older healthy control group. See figure 3.2. Figure 3.3 gives an example of 
SUV parametric images for TBI, AD and healthy older control. 
  
3.4.2 Neuropsychological assessment 
TBI patients have a characteristic pattern of cognitive impairment. Generally there is 
information processing speed, memory and executive function. TBI patients showed poorer 
information processing speeds with higher colour naming and choice reaction times and 
poorer executive functioning, exemplified by poorer Stroop Inhibition times (see table 3.2). 
TBI subjects also demonstrated a wider spread of performance within the group with some 
subjects performing particularly badly. One TBI subject also could not be fully assessed 
because of limited use of his hands. 
 
3.5 Discussion 
In this study we investigated a wide spectrum of chronic TBI subjects. The time range from 
event to scanning was extensive ranging from 11 months to 17 years, the range of disability 
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varied from none to speech and movement impaired and over half had structurally abnormal 
MRI scans. Neuropsychology results demonstrated deficits that are expected in TBI with 
slowing of complex processing. Despite these factors we were not able to identify any 
differences in [11C]-PIB uptake compared to an older healthy control group. Within the 
limitations of this study this would suggest the absence of significantly elevated β amyloid 
plaque deposition in the TBI group. 
 
On initial consideration this result seems unexpected given the fact that subjects have 
impaired neuropsychological assessment. These results may however be explained by the 
specificity and sensitivity of which [11C]-PIB to bind to β pleated amyloid fibrils. It does not 
label the whole family of compounds that originate from the enzymatic cleavage of APP  5. 
Included in this cohort are the soluble APP (sAPP) proteins produced by first cleavage by α 
or β secretase and the resultant intermediary being acted on by ϒ secretase15-18. Soluble 
APP is undoubtedly physiologically important in cerebral function binding to an LDL 
cholesterol receptor, a class A scavenger receptor and fibulin-1 (which is predominantly 
expressed on neurons in the brain). It has the ability to activate guanylate cyclase, regulate 
membrane excitability, calcium homeostasis and down regulate NMDA receptor mediated 
currents15,19. Cleavage also produces potentially neurotoxic side products, the most 
interesting of which are the amyloid β (Aβ) fragments varying in size from 39 – 43 amino 
acids. Aβ exists as monomers, dimers and higher oligomers20,21. These soluble moieties do 
not bind [11C]-PIB and it is only with further aggregation into protofibrils and then fibrils that 
thioflavine staining is seen. This process requires both time and the attainment of a certain 
critical concentration of Aβ suggested by in vitro studies. The result is a “lag” phase during 
which no aggregation is detected, but after which it proceeds very rapidly  22,23. It may be that 
TBI subjects scanned were all still in this lag period with no formal plaque deposition at the 
time of investigation. Non-fibrillar Aβ arranged oligomers are neurotoxic inhibiting long term 
potentiation possibly by binding to nicotinic receptors on pyramidal cells and GABAergic 
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interneurons. Interestingly, in one series, immunohistochemistry confirmed the presence of 
Aβ42 intra-cerebrally at least one year after severe TBI but only 30% of that group had 
actual amyloid plaque formation24. 
 
 It should also be recognised that β amyloid and the amyloid group of molecules may in fact 
not be the main drivers of neuronal damage in TBI. Hyperphosphorylated tau, the main 
component of toxic neurofibrillary tangles (NFT), must also be considered. On 
immunohistochemistry, NFT were found in over 30% of TBI subjects under the age of 60. 
Hyperphosphorylated tau is present 2 – 3 hours after severe brain injury and tau pathology is 
the major finding in pugilistic encephalopathy 15, 24, 25. In the acute scenario, the location of 
tau deposits post TBI seems to be related to the site of injury and is likely to reflect the 
shearing stresses undergone by damaged axons. A year after TBI the distribution of tau is 
more widespread and excessive24. Investigating the presence and distribution of tau was 
outside the scope of my study but a hunt for confirmation of its presence would seem to be 
useful investigation.   
 
Continued thalamic microglial activation has also been demonstrated in this group of 
patients 26. The result is the creation of a neuronal microenvironment rich in cytokines and 
chemokines. At the time of TBI this reaction helps transform and maintain microglial in their 
activated phagocytic phenotype, actively clearing cellular debris. In the chronic scenario, 
continued activation maybe responsible indiscriminate neuronal death independent of fibrillar 
amyloid. 
 
Of the eight TBI subjects investigated, five had structurally abnormal MRI’s with significant 
areas of focal atrophy. Careful consideration thus had to be made about the technique used 
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in [11C]-PIB analysis. The calculation of SUV’s is a well-recognised and frequently used 
technique in oncology to monitor for tumour recurrence  27-29. Its use in [11C]-PIB analysis 
has also been tested and SUV cerebellar-RATIO images have been shown to be reliable14 
but the SUV analysis as performed in this study has not been validated. The lack reference 
region in this study however should be considered a major limitation. Spectral analysis using 
an arterial input function may have produced more definitive results. During analysis the PET 
parametric data were never modified or warped into standard space. This was especially 
important in areas of focal atrophy where spatial normalisation could result in dilution of the 
[11C]-PIB signal. Instead the atrophied lobe was masked from the analysis and the signal 
from the contralateral lobe was compared with controls. It could be argued that these 
atrophied lobes are in fact the areas where amyloid plaque deposition begins but raised 
[11C]-PIB signal was not visually evident in these areas. Partial volume correction may 
however enable more objective analysis but would result in the modification of the raw PET 
data with the potential for introducing noise into genuine signal. Finally, the control and TBI 
groups were not equally matched. Control subjects where older and may have had an 
increased amyloid load30. This may explain the tendency for lower binding in patients as 
compared to control. Comparison with age matched controls may thus produce different 
result but this question could not currently be addressed. Despite these limitations the 
results were supported by visual image interpretation, as none of the cases showed an 
increase of cortical uptake similar to white matter as commonly observed in AD. 
 
In conclusion we have demonstrated a lack of significant [11C]-PIB uptake in chronic TBI 
patients. We have confirmed that this group of patients do suffer with neuropsychological 
impairment but β amyloid plaque formation is not likely to be responsible for this. Other 
neurotoxic molecules should also be considered as driving this. Of these the amyloid 
oligomers are of particular interest as they may exist for an undetermined period of time 
before plaque formation occurs. 
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3.6 Tables 
Table 3.1. Clinical features of all traumatic brain injury (TBI) patients 
Age Sex Highest level 
of education 
Cause of 
TwhandaerBI 
GCS 
when 
found 
Post-
traumatic 
amnesia 
(hrs) 
Current 
medications 
Scanning 
interval 
from time 
of injury 
(months) 
45 M Postgraduate Unknown 4 24 Gabapentin 
Modafenil 
Amitriptyline 
72 
 
55 M Postgraduate Hit plank of 
wood then fell 
onto concrete 
 
4 UK nil 36 
42 M A level Pedestrian hit 
by a car 
 
4 432 nil 72 
42 M O level Motorcycle 
accident 
 
4 UK Tropium 
chloride 
Folic acid  
204 
40 M Graduate 
degree 
Motorcycle 
accident 
 
4 1008 nil 132 
42 F Postgraduate  Pedestrian hit 
by a car 
 
3 144 Codine 
Paracetamol  
72 
49 M A level ?assault 
 
4 2 nil 11 
38 M Graduate Motorcycle 
accident 
 
6 UK Citalopram 
Modafanil 
Omeprazole 
108 
UK – unknown  
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Table 3.2: Sample of Neuropsychological test results: traumatic brain injury and control 
patients demonstrating impaired planning and executive function. Memory (not shown) was 
not affected. 
COGNITIVE DOMAIN 
 
COGNITIVE VARIABLE TBI 
Mean±SD
 
CONTROL 
Mean±SD(a)
 
TBI vs.  
CONTROL 
(P value) 
Intellectual ability: 
Reading  
Verbal 
Non-verbal 
 
WTAR age-scaled score 
WASI Similarities 
WASI Matrix Reasoning 
 
109.4±8.9 (N=7) 
39.4±4.2 (N=7) 
28.9±2.4 (N=8) 
 
112±9.8 (N=15) 
34.5±6.3 (N=15) 
26.8±5.0 (N=15) 
 
0.435 
0.104 
0.359 
Executive function 
Inhibition 
Cognitive flexibility 
 
 
Inhibition – naming (s) 
Inhibition/switching – 
naming + reading ÷ 2 (s) 
 
39.3±13.5 (N=7) 
33.6±9.1 (N=7) 
 
28.7±17.6  
(N=15) 
32.2±10.5 
(N=14) 
 
0.006 
0.015 
 
Processing speed:    
                       Visual 
search 
                               
Complex 
                                 
Naming 
                                
Reading 
                               
Complex  
            Choice 
reaction time 
 
TMT Trail A (s) 
TMT Trails B (s) 
Colour Naming (s) 
Word Reading (s) 
Inhibition (s) 
CRT median RT (ms) 
 
33.6±16.3 
(N=10) 
60.3±30.4 
(N=10) 
39.3±13.5 (N=7) 
27.9±6.3 (N=7) 
73.6±33.4 (N=7) 
450±65 (N=7) 
 
19.7±4.5 (N=14) 
43.0±12.6 
(N=14) 
33.2±.4.0 (N=14) 
28.9±6.3 (N=15) 
23.3±4.4 (N=15) 
408±51 (N=15) 
 
0.006 
0.074 
0.006 
0.812 
0.000 
0.097 
Neuropsychological results for TBI patient and age-matched control group. (a) Following 
exploratory data analysis control subjects identified as extreme outliers (≥ 3 x interquartile 
range) were excluded. WTAR = Wechsler Test of Adult Reading. WASI = Wechsler 
Abbreviated Scale of Intelligence; Inhibition, Inhibition/Switching, Letter Fluency, Colour 
Naming, and Word Reading subtests are from the Delis-Kaplan Executive Function 
System Color-Word Interference Test; TMT = Trail Making Test; CRT = Choice-Reaction 
Task 
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3.7 Figures 
 
Figure 3.1. [11C]-PIB  Standardised Uptake Values (SUV) in control and TBI subjects. 
Regions sampled include TL=temporal lobe, FL=frontal lobe, PL=parietal lobe, OL=occipital 
lobe, Cere=cerebellum, BS=brain stem, Cig=cingulate, thalamus and striatum. SUV similar 
in all regions sampled. 
                                                                                                                                                                                          
 
Figure 3.2. Sample [11C]-PIB SUV binding potential parametric images for A – Alzheimers 
Disease subject, MMSE<25, B – Control and C – TBI subject. [11C]-PIB uptake greater in 
AD but similar in control and TBI subjects. 
 
 
 
 
99 
 
3.8 References 
1. Maas AI, Stocchetti N, Bullock R. Moderate and severe traumatic brain injury in adults. 
Lancet Neurol. 2008;7:728-41.  
 
2. Shively S, Scher AI, Perl DP, Diaz-Arrastia R. Dementia Resulting From Traumatic Brain 
Injury: What Is the Pathology? Arch Neurol. 2012; 9:1-7. 
 
3. Dixon CE, Kochanek PM, Yan HQ, Schiding JK, Griffith RG, Baum E, Marion DW, 
DeKosky ST.One-year study of spatial memory performance, brain morphology, and 
cholinergic markers after moderate controlled cortical impact in rats. J Neurotrauma. 
1999;16:109-22. 
 
4. GentlemanS.M., Leclercq P.D., Moyes L., Graham D.I., Smith C., Griffin W.S.T., Nicoll 
J.A.R. Long-term intracerebral inflammatory response after traumatic brain injury. 
Forensic Science International  2004; 146: 97–104 
 
5. Swahn BM, Wensbo D, Sandell J, Sohn D, Slivo C, Pyring D, Malmström J, Arzel E, 
Vallin M, Bergh M, Jeppsson F, Johnson AE, Juréus A, Neelissen J, Svensson S. 
Synthesis and evaluation of 2-pyridylbenzothiazole, 2-pyridylbenzoxazole and 2-
pyridylbenzofuran derivatives as 11C-PET imaging agents for beta-amyloid plaques. 
Bioorg Med Chem Lett. 2010;20:1976-80. 
 
100 
 
6. Mathis CA, Mason NS, Lopresti BJ, Klunk WE.Development of Positron Emission 
Tomography β-Amyloid Plaque Imaging Agents. Semin Nucl Med. 2012;42:423-32.  
 
7. Edison P, Brooks DJ, Turkheimer FE, Archer HA, Hinz R. Strategies for the generation of 
parametric images of [11C]PIB with plasma input functions considering discriminations 
and reproducibility. Neuroimage. 2009;48:329-38 
 
8. Johnson KA, Fox NC, Sperling RA, Klunk WE. Brain imaging in Alzheimer disease. Cold 
Spring Harb Perspect Med. 2012;2:a006213 
 
9. Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Någren K, Bullock R, 
Walker Z, Kennedy A, Fox NC, Rossor MN, Rinne JO, Brooks DJ. Conversion of amyloid 
positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology. 
2009;73:754-60. 
 
10. Okello A, Edison P, Archer HA, Turkheimer FE, Kennedy J, Bullock R, Walker Z, 
Kennedy A, Fox N, Rossor M, Brooks DJ. Microglial activation and amyloid deposition in 
mild cognitive impairment: a PET study. Neurology. 2009;72:56-62. 
 
11. Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L, Mitchell TN, Brooks DJ, 
Duncan JS. Three-dimensional maximum probability atlas of the human brain, with 
particular reference to the temporal lobe. Hum Brain Mapp. 2003;19:224-47. 
101 
 
12. Joachim CL, Morris JH, Selkoe DJ. Diffuse senile plaques occur commonly in the 
cerebellum in Alzheimer's disease. Am J Pathol. 1989;135:309-19. 
 
13. Yamaguchi H, Hirai S, Morimatsu M, Shoji M, Nakazato Y. Diffuse type of senile plaques 
in the cerebellum of Alzheimer-type dementia demonstrated by beta protein 
immunostain. Acta Neuropathol. 1989;77:314-9 
 
14. Yaqub M, Tolboom N, Boellaard R, van Berckel BN, van Tilburg EW, et al. Simplified 
parametric methods for [11C]PIB studies. Neuroimage. 2008 Aug 1;42(1):76-86. 
 
15. Turner PR, O’Connor K, Tate WP, Abraham WC. Roles of amyloid precursor protein and 
its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol. 
2003;70:1-32 
 
16. Esler W.P., Wolfe M.S. A portrait of Alzheimer secretases—new features and familiar 
faces. Science. 2001;293:1149–454. 
 
17. Yan R., Bienkowski M.J., Shuck M.E., Miao H., Tory M.C., Pauley A.M., Brashier J.R., 
Stratman, N.C., Mathews, W.R., Buhl, A.E., Carter, D.B., Tomasselli, A.G., Parodi, L.A., 
Heinrikson, R.L., Gurney, M.E. 1999. Membrane-anchored aspartyl protease with 
Alzheimer’s disease beta-secretase activity. Nature. 1999; 402: 533–37. 
 
102 
 
18. Wolfe, M.S., Xia, W., Ostaszewski, B.L., Diehl, T.S., Kimberly, W.T., Selkoe, D.J. Two 
transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and 
gamma-secretase activity. Nature.1999; 398:513–17. 
 
19. Herz, J., Strickland, D.K. LRP: a multifunctional scavenger and signalling receptor. J. 
Clin. Invest. 2001; 108:779–84. 
 
20. Walsh, D.M., Klyubin, I., Fadeeva, J.V., Cullen, W.K., Anwyl, R., Wolfe, M.S., Rowan, 
M.J., Selkoe, D.J. Naturally secreted oligomers of amyloid _ protein potently inhibit 
hippocampal long-term potentiation in vivo. Nature 2002;416:535–39. 
 
21. Walsh, D.M., Klyubin, I., Fadeeva, J.V., Rowan, M.J., Selkoe, D.J. Amyloid-beta 
oligomers: their production, toxicity and therapeutic inhibition. Biochem. Soc. Trans. 
2002;30:552–57. 
 
22. Harper, J.D., Lansbury, P.T., Models of amyloid seeding in Alzheimer’s disease and 
scrapie: mechanistic truths and physiological consequences of the time-dependent 
solubility of amyloid proteins. Annu. Rev. Biochem. 1997;66:385–407. 
 
23. Jarrett, J.T., Berger, E.P., Lansbury Jr., P.T., The carboxy terminus of the beta amyloid 
protein is critical for the seeding of amyloid formation: implications for the pathogenesis 
of Alzheimer’s disease. Biochemistry. 1993;32:4693–97. 
103 
 
24. Johnson VE, Stewart W, Smith DH. Widespread Tau and Amyloid-Beta Pathology Many 
Years After a Single Traumatic Brain Injury in Humans Brain Pathology. 2012;22:142–49 
 
25. McKenzie K. J., McLellan D. R., Gentleman S. M., Maxwell W. L., Gennarelli T. A., 
Graham D. I. Is β-APP a marker of axonal damage in short-surviving head injury? Acta 
Neuropathol. 1996; 92: 608–13 
 
26. Ramlackhansingh AF, Brooks DJ, Greenwood RJ, Bose SK, Turkheimer FE, Kinnunen 
KM, Gentleman S, Heckemann RA, Gunanayagam K, Gelosa G, Sharp DJ. Inflammation 
after trauma:microglial activation and traumatic brain injury. Ann Neurol. 2011;70:374-83. 
 
27. Shepherd T, Owenius R. Gaussian process models of dynamic PET for functional 
volume definition in radiation oncology.IEEE Trans Med Imaging. 2012;31:1542-56. 
 
28. Westerterp M, Pruim J, Oyen W, Hoekstra O, Paans A, Visser E, van Lanschot J, Sloof 
G, Boellaard R. Quantification of FDG PET studies using standardised uptake values in 
multi-centre trials: effects of image reconstruction, resolution and ROI definition 
parameters. Eur J Nucl Med Mol Imaging. 2007;34:392-404. 
 
29. Ly J, Garpered S, Höglund P, Jönsson E, Valind S, Edenbrandt L, Wollmer P. Semi-
automatic analysis of standard uptake values in serial PET/CT studies in patients with 
lung cancer and lymphoma. BMC Med Imaging. 2012;12:6. 
104 
 
30. Villemagne VL, Pike KE, Darby D, Maruff P, Savage G, Ng S, et al. Abeta deposits in 
older non-demented individuals with cognitive decline are indicative of preclinical 
Alzheimer's disease. Neuropsychologia. 2008;46(6):1688-97. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
105 
 
Chapter 4 
 
Amyloid deposition & metabolic changes in 
Posterior Cortical Atrophy 
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4.1. Amyloid deposition and metabolic changes in Posterior Cortical Atrophy  
In this Chapter I will be focusing on the atypical form of AD, Posterior Cortical Atrophy. This 
is a particularly rare form of AD where there is significant posterior cortical involvement. In 
this Chapter I would like to address the particular question, does the deposition of amyloid 
match the areas most affected by cortical atrophy and cerebral metabolism?   
 
Summary of Objectives 
Atypical presentations of sporadic Alzheimer’s disease are rare and can be diagnostically 
challenging. Posterior Cortical Atrophy (PCA), is such a syndrome, characterized by deficits 
of visuospatial processing, such as reading, object and facial recognition, as the presenting 
complaint. In vivo investigations into PCA, using PET, have demonstrated reduced cerebral 
metabolism and fibrillar amyoid deposition. However these studies have not been extensive 
and results have been inconsistent. Here we make use of the PET tracers [11C]-PIB and 
[18F]-FDG to investigate changes in amyloid deposition and cerebral metabolism in PCA.  
 
Eight patients with PCA, 12 patients with sporadic AD and 13 healthy controls (HC) were 
investigated. We evaluated brain amyloid load with [11C]-PIB PET and glucose metabolism 
with [18F]-FDG. All patients had a neuropsychological assessment (with 5 undergoing 
extensive neuropsychological testing) and MRI. Cerebellar RATIO images of [11C]-PIB 
uptake were generated and anatomical regions of interest (ROI’s) sampled.  Parametric 
maps of absolute cerebral glucose metabolism were generated with spectral analysis using 
an arterial input function for [18F]-FDG studies. Pre-defined ROI’s were sampled and voxel 
based analyses were performed with both [11C]-PIB and [18F]-FDG scans comparing PCA, 
normal HC and sporadic AD group findings. 
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Summary of Results 
Cortical [11C]-PIB binding in the PCA group was raised in the frontal, parietal, temporal and 
occipital cortex compared with HC (P < 0.05).  There was no difference in levels of [11C]-PIB 
retention between the sporadic AD and PCA groups in all cortical areas. Cortical [18F]-FDG 
retention in the PCA group was deceased in the frontal, parietal, temporal and occipital 
cortex compared with HC (P < 0.05). [18F]-FDG retention was significantly lower in the 
temporal and occipital cortex in the PCA group compared to sporadic AD. All PCA patients 
showed parietal cortical atrophy on MRI.  
 
Our findings support the concept of PCA being a subgroup of sporadic AD with both 
conditions having similar patterns of [11C]-PIB uptake. However the metabolic 
consequences of this deposition differ, with reduced [18F]-FDG uptake targeting the occipital 
and temporal cortices of the PCA group.  
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4.2 Introduction 
PCA is a rare progressive neurodegenerative condition characterized by early visuospatial 
deficits. Early features include the Balint’s syndrome consisting of simultanagnosia (the 
inability to perceive the visual field as a whole), ocular apraxia (difficulty in fixating the eyes) 
and optic ataxia (an inability to locate objects using vision). Later in the disease process the 
Gertsmann’s syndrome consisting of visual agnosia, alexia, agraphia, and transcortical 
sensory aphasia develops1 invariably followed by memory impairment and features typically 
associated with sporadic AD. For this reason PCA has been considered to be a focal 
presentation of sporadic AD with early involvement of the visuo-spatial network. This view 
has been strengthened by post-mortem studies demonstrating characteristic features of 
Alzheimer´s disease with senile plaques and neurofibrillary tangles in PCA1. Neurofibrillary 
tangles densities were however lower in PCA subjects compared to sporadic AD. 
 
[11C]-PIB PET is a marker of fibrillar amyloid arranged into β pleated sheets2. AD patients 
show twofold increases in mean [11C]-PIB binding in cortical areas3. As discussed in section 
1.3, [18F]-Fluoro-2-deoxy-D-glucose ([18F]-FDG) is a PET tracer taken up by metabolically 
active neurones. As a glucose analogue it becomes phosphorylated but becomes trapped 
within metabolically active cells. Its retention is thus a marker of hexokinase activity 
reflecting cerebral glucose metabolism4. In sporadic AD, characteristic reductions in [18F]-
FDG uptake, were found in neocortical association areas including the posterior cingulate, 
precuneus, temporoparietal and frontal multimodal association regions; the primary visual 
cortex, sensorimotor cortex, basal ganglia and cerebellum were relatively spared5.  
 
Studies utilizing these tracers in PCA are however limited and have produced conflicting 
results. Short case series and single subject case reports have mostly shown a similar 
pattern of [11C]-PIB retention in PCA and sporadic AD. It has been suggested however that 
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this uptake has a greater tendency to focus on the posterior parts of the brain6. More 
consistent however is the demonstration of reduced [18F]-FDG retention in the posterior 
regions of the brain suggesting occipital lobe hypometabolism7,8,9,10. Only one study currently 
exists in the published literature where both [11C]-PIB and [18F]-FDG scans have been 
performed on PCA subjects8. Again the discordance between [11C]-PIB uptake and 
hypometabolism was highlighted. 
 
In this study I hypothesised that fibrillar amyloid deposition would be independent of the 
metabolic changes seen in PCA. I have performed both [11C]-PIB and [18F]-FDG scans on 
PCA subjects along with neuropsychological assessment and structural MRI scanning.  
 
4.3 Methods 
4.3.1 Posterior Cortical Atrophy subjects 
Eight PCA subjects were recruited from outpatient memory clinics of UK hospitals. Patients 
were assessed by at least two Neurologists. PCA was defined clinically according to criteria 
set out by Tang-Wai DF 20041. The presence of signs and symptoms suggestive of 
dementia with Lewy bodies (DLB) – early visual hallucinations, extrapyramidal features and 
cognitive fluctuations, sporadic AD – early memory impairment or the presence of 
ophthalmological disease were exclusion criteria. Subjects with significant cerebrovascular 
pathology based on MRI rating scales were also excluded11. See table 4.1 for a clinical 
summery of all PCA subjects.  
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4.3.2 Sporadic AD and Healthy Control subjects 
Twelve sporadic AD patients fulfilled the diagnosis of probable AD according to the criteria of 
the National Institute of Neurological and Communication Disorders, Alzheimer’s Disease 
and Related Disorders Association (NINCDS-ADRDA)12. These subjects were recruited as 
part of an earlier study on [11C]-PIB uptake and [18F]-FDG retention in sporadic AD3. 
Thirteen HC were also recruited as part of this earlier study. They underwent clinical and 
neuropsychological assessments to ensure that there were no underlying neurological 
illnesses. Not all sporadic AD and HC subjects had both [18F]-FDG and [11C]-PIB scans, 
meaning 8 subjects were recruited into each scan group. See table 4.2 for a summary of the 
clinical details of all cohorts. 
 
 4.3.3 Neuropsychological assessment 
During the study period, 5 of the 8 PCA subjects completed Neuropsychological 
assessments. This was performed by a psychologist at Charing-Cross Hospital, London, UK. 
They underwent a battery of neuropsychological tests that included; Mini Mental State 
Examination13, test of attention (digit span), episodic memory (story recall), visual perception 
(fragmented letters), construction (block design), verbal reasoning (similarities), reading 
(WTAR)14, visual naming (GNT)15 and Rey figure. 
 
Neuropsychological profile for all of the HC and AD patients, were also obtained and have 
been described previously3. 
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4.3.4 MRI image acquisition 
All subjects underwent volumetric T1 and T2-weighted MRI for the identification of any 
underlying structural lesions and for the subjective quantification of cerebro-vascular 
disease. All scans were reviewed by a consultant neuro-radiologist. Volumetric T1 weighted 
images were also coregistered to PET images for the generation of subject specific atlases. 
All PCA subjects were scanned using a 3T Philips scanner while sporadic AD and HC 
subjects were scanned using a 1.5T GE scanner.  
 
4.3.5 PET image acquisition 
All subjects were scanned using a Siemens ECAT 962 EXACT HR+ scanner which has an 
axial view of 15.5 cm. Prior to scanning, intravenous access was secured in the antecubital 
fossa of each subject. A 10 minute transmission scan was acquired before the emission 
study, using a single rotating photon point source of 137Cs, for subsequent attenuation and 
scatter correction. The PET data were acquired in 3-dimensional mode. Data were 
reconstructed using filtered back projection to produce images containing 63 contiguous 
slices, separated by 2.42mm, of 128x128 pixels 2.092mm square. Reconstruction of 
emission data was carried out using filtered back projection. The 3D emission data were 
Fourier-rebinned into 2D data sets to increase the speed of reconstruction. The 
reconstructed images consisted of sixty-three transaxial image planes were displayed as 
2.46-mm slices with a reconstructed axial resolution of 5.4 mm and a transaxial resolution of 
5.6 mm.  
 
[11C]-PIB scans 
Following the transmission scan and 30 seconds after the start of the emission scan, all 
subjects received 371.931.1MBq [11C]-PIB injected IV. This was followed by a 90 minute 
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dynamic emission scan consisting of 32 different time frames. [11C]-PIB was manufactured 
by Hammersmith Imanet, GE Healthcare at the Cyclotron Building, Hammersmith Hospital.  
 
[18F]-FDG scans 
To ensure standardized [18F]-FDG uptake, subjects were asked to fast for 4 hours before 
scanning. An arterial line was inserted into the radial artery at the level of the wrist to enable 
arterial  blood sampling to be performed during the emission scan. This enabled spectral 
analysis to be preformed. At the start of the scan a bolus injection of 188.7±6.9MBq of [18F]-
FDG was injected 30 seconds after the start of the emission scan. A 60-minute dynamic 
emission scan was then acquired using predefined protocol consisting of 28 time frames. 
Continuous online sampling was performed for 15 minutes and then discrete blood samples 
were taken at baseline, 5, 10, 15, 20, 30, 40, 50, and 60 minutes. A hematocrit was 
estimated from the baseline blood sample and plasma glucose levels were measured on 
selected samples. 
 
4.3.6 Image analysis 
All image processing were performed using Analyze (Mayo Clinic, MN) and SPM2 
(Wellcome Department of Imaging Neuroscience, University College London, UK) running in 
MATLAB 5 (R12, Mathworks, Natick, MA). In this study two forms of PET data analysis were 
undertaken. Firstly region of interest analysis was done and followed secondly by 
exploratory statistical parametric mapping analysis. Reference should be made to section 
1.4 for flow diagrams outlining these methods. 
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 [11C]-PIB PET – Region of Interest  
Time frames corresponding to 10-90 minute (early and late) and 60-90 minute (late) 
summation images were created for each [11C]-PIB scan. Each subject MRI was then 
coregistered to its corresponding early PET scan and segmented into grey matter, white 
matter and cerebrospinal fluid (CSF). An in house atlas16 was then normalized and 
convolved with the grey matter segment. Individualized cortical grey matter regions were 
thus defined and applied onto its corresponding late [11C]-PIB scan. The late (60 – 90 
minute) scan reference region RATIO approach was used because it provides a robust 
measure of total: nonspecific PIB relative volumes of distribution in target brain regions 
without the need for arterial sampling. The cerebellum was chosen as a reference region in 
the analysis as it has been found to contain only amorphous amyloid plaques that are not 
detected with thioflavin or Congo red. Cerebellar [11C]-PIB uptake is thus thought to 
represent baseline, background retention and radioactivity. Using Analyze software, 
cerebellar [11C]-PIB activity was sampled and the late summation images were normalised 
to the mean cerebellar cortical uptake value over this 60-90 minute period, generating the 
late target:cerebellar RATIO image. Cortical RATIO values for frontal, temporal, parietal, 
occipital lobes and the whole brain were sampled. 
 
[18F]-FDG – Region of Interest 
Parametric maps of absolute regional cerebral glucose retention (rCMRGlc) were generated 
with spectral analysis using an arterial input function as previously described3. PET time 
frames 24 to 28 were summated and the corresponding subject MRI coregistered to the 
resultant PET add image. White matter has only low metabolism and so only grey matter 
MRI map was considered for analysis. Grey matter maps were generated by first normalizing 
the in house atlas to the coregistered whole MRI and followed by multiplication with the grey 
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matter MRI segment. Cortical frontal, temporal, parietal, occipital lobes and the whole brain 
were sampled.  
 
4.3.7 Statistical Analysis 
Statistical analyses were performed using SPSS for Windows version 16 (SPSS, Chicago, 
IL). Between groups regional differences were analysed using Mann-Whitney U 
nonparametric test statistical level set at p < 0.05. 
 
4.3.8 Statistical Parametric Mapping (SPM)  
Between group comparisons of PET scans were done. We used SPM to interrogate groups 
of scans. PET images of each group (PCA, AD and HC) were compared statistically 
producing a map of voxel clusters of significantly increased or decreased tracer uptake.  
 
Using SPM2 [11C]-PIB target:cerebellar ratio images and parametric rCMRGlc images were 
normalized to the Montreal Neurological Institute (MNI) template provided with SPM2. 
Normalized scans, were then spatially smoothed using a 10 x 10 x 10 mm (full-width at half 
maximum) isotropic Gaussian kernel. This spatial filter attempts to accommodate for inter-
subject anatomic variability and improves signal to noise for statistical analysis.  
 
SPM comparisons were then performed using appropriately weighted contrasts to localize 
significant increases or decreases in mean voxel uptake values in patients. The contrasts 
were used to derive Z scores on a voxel basis using the general linear model17.  
  
115 
 
Comparisons between HC, sporadic AD and PCA groups with [11C]-PIB target:cerebellar 
RATIO images and parametric rCMRGlc uptake were performed using a threshold of p 
<0.001 with a cluster extent threshold of 50 voxels per cluster.  
 
Global binding potential normalization was omitted allowing a pattern of tracer uptake to be 
revealed. Any resulting cluster with a corrected p value (cluster level) of <0.05 was 
considered significant. Voxels showing significant results were overlaid onto the T1 MRI 
template image provided by SPM.  
 
Ethical approval for this study was obtained from the Ethics Committees of Hammersmith 
and Queen Charlotte’s Hospitals, while permission to administer radiotracers was obtained 
from the Administration of Radioactive Substances Advisory Committee (ARSAC) UK. 
Informed written consent was obtained from all participating subjects. 
 
4.4 Results 
4.4.1 Subjects 
A total of 8 PCA subjects were recruited into the study. All completed MRI, [11C]-PIB and 
[18F]-FDG PET scans while complete neuropsychological assessments were completed in 5 
subjects. Twelve sporadic AD subjects were investigated. MRI scanning and 
neuropsychology was completed on all 12, 9 completed [11C]-PIB scans and 8 completed 
[18F]-FDG scans. Thirteen HC were investigated. Again, all completed neuropsychology and 
MRI scanning but 9 completed [11C]-PIB scans and 8 completed [18F]-FDG scans.  
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All cohorts were however similarly matched for age and for the PCA and sporadic AD groups 
disease duration and years of education. 
 
4.4.2 PET analysis 
4.4.2.1 [11C]-PIB  
ROI analysis of [11C]-PIB data 
Cortical [11C]-PIB binding was significantly higher in the frontal, parietal, temporal and 
occipital cortex in both the sporadic AD and PCA groups compared with HC (P < 0.01). 
Higher uptake was also seen in the anterior and posterior cingulate and in the subcortical 
regions thalamus and striatum (P<0.01). The PCA [11C]-PIB binding pattern was similar to 
Alzheimer disease in all cortical and subcortical regions compared with sporadic AD 
patients. Interestingly [11C]-PIB binding in the occipital cortex was similar between the PCA 
and sporadic AD group (P = 0.114). 
 
SPM analysis of [11C]-PIB data 
Four comparisons were undertaken: sporadic AD>HC, PCA>HC, PCA<sporadic AD and 
sporadic AD<PCA.  
 
Sporadic AD>HC and PCA>HC 
In both comparisons it was expected that there would be increased [11C]-PIB retention in 
dementia groups. Of interest the pattern retention was similar in both sporadic AD and PCA. 
Affected areas included the cortical frontal, temporal, parietal lobes and the anterior and 
posterior cingulate. In both sporadic AD and PCA groups the occipital lobes were largely 
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unaffected when compared to HC group. 
 
PCA<sporadic AD and sporadic AD<PCA 
The posterior cerebral dysfunction typical in PCA subjects would suggest a higher tendency 
to involve the posterior parts of the brain. Despite this [11C]-PIB Z scores were greater in 
sporadic AD than PCA. No significant voxel clusters were identified when [11C]-PIB uptake 
was compared between PCA and sporadic AD groups.  
 
4.4.2.2 [18F]-FDG 
ROI analysis of [18F]-FDG retention 
Cortical [18F]-FDG retention was reduced in the frontal, parietal and temporal lobes and in 
the posterior cingulate in sporadic AD groups compared with HC (P < 0.05). Decreases in 
[18F]-FDG uptake were also widespread in the PCA group when compared to HC. In the 
cortex of the temporal, parietal and occipital lobes changes were highly significant (P=0.001) 
while retention in the frontal cortex and thalamus was also significantly decreased (P=0.012 
and P=0.005 respectfully).   
 
These differences in [18F]-FDG retention, were further demonstrated by comparing the PCA 
group with sporadic AD.  Here the temporal and occipital lobe retention were relatively lower 
in the PCA group (P=0.027 and P=0.036 respectively).  
  
SPM analysis of [18F]-FDG 
Four comparisons were again undertaken: sporadic AD<HC, PCA<HC, PCA<sporadic AD 
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and sporadic AD<PCA.  
 
Sporadic AD<HC and PCA<HC 
Significant voxel clusters of decreased cortical [18F]-FDG retention were seen in the 
posterior parietal lobe and the temporal lobe when sporadic AD was compared to HC. A 
similar pattern of hypometabolism as compared to [11C]-PIB was expected but not found 
when PCA was compared to HC. 
 
PCA<sporadic AD and sporadic AD<PCA 
Areas of relatively decreased [18F]-FDG retention were identified in the cortical posterior 
parietal and occipital lobes for the comparison PCA<sporadic AD. Of interest, the right 
hemisphere appeared to be involved to a greater extent than the left. No significant voxel 
clusters were identified for the comparison sporadic AD<PCA. 
Figures 4.1, 4.2 and 4.3 summarises these results. 
 
4.4.3 MRI 
All PCA patients showed regional posterior cerebral cortical atrophy.  Sporadic AD subjects 
demonstrated the typical distribution of atrophy involving the cortices of all lobes. Control 
MRI’s were normal. 
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4.4.4 Neuropsychological assessment 
Neuropsychological assessment on 5 PCA patients is summarised on table 4.2. As expected 
in PCA subjects, tasks involving visual input were severely affected with the relative 
preservation of episodic and working memory, figure 4.4.   
 
4.5 Discussion 
4.5.1 [11C]-PIB binding is similar in PCA and sporadic AD. 
PCA is a rare progressive neurodegenerative disorder characterized by neurofibrillary tangle 
and amyloid plaque deposition. Results support the view that PCA is an AD variant as no 
differences were identified in regional amyloid deposition when compared to sporadic AD. In 
vivo amyloid deposition thus appears to be similar in PCA and sporadic AD, a finding also 
demonstrated in a recent series of 15 PCA patients imaged with PIB8. These results are also 
supported by PM studies demonstrating an AD pattern of amyloid plaques deposition in 
PCA1. This pattern of amyloid deposition is however by no means a consistent finding. 
Smaller studies, consisting mostly of case reports, have demonstrated and increased 
posterior parietal or occipital lobe PIB uptake. These studies were, however, weakly 
powered.  
 
The presence of marked posterior parietal and occipital atrophy, however, may have 
influenced the quantitation of PET results. The apparent lack of occipital PIB binding might 
be related to the extent of posterior cerebral atrophy found in PCA subjects. During the 
analysis process the normalization of images onto standardised brains can also result in the 
warping of subject scans in areas of focal atrophy. The result can be a further dilution of the 
PIB signal with the production of spurious results. We have however attempted to minimise 
this complication by not modifying raw PET data during ROI analysis. Rather individualized 
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subject atlases were created by normalizing the standard atlas onto the subjects MRI scan. 
Regions were thus defined in a reliable manner.  
 
4.5.2 [18]-FDG uptake was significantly reduced posteriorly in PCA subjects.  
Defects in metabolism were expected to be seen in both PCA and sporadic AD. On ROI 
analysis sporadic AD had reduced metabolism in all cortical regions except for the occipital 
lobe. The sparing of this can be expected with the late involvement of visual deficits in 
sporadic AD.  
 
PCA subjects had an overall lower binding of [18]-FDG compared to sporadic AD subjects, 
although this difference was not significant. This likely reflects the greater clinical severity of 
PCA with its occurrence in a younger age group and a more aggressive progression that 
sporadic AD. Hypometabolism affected all cortical regions in the PCA group. The 
involvement of the occipital lobe can be expected given the early visual impairment 
described by subjects. Of interest however is the demonstration of hypometabolism in the 
thalamus of PCA subjects. The involvement of the subcortical regions has not been 
previously described in PCA and may represent the more rapid progression of the disease 
process in the cohort we have examined.  
 
4.5.3 Posterior metabolism, significantly lower in PCA than sporadic AD. 
Given the clinical features, it is not surprising to identify posterior hypometabolism in PCA. 
However the discordance between amyloid fibrillar deposition (as identified by [11C]-PIB 
uptake) and reduced FDG uptake is of interest. It would suggest that fibrial amyloid may not 
directly be related to neuronal damage and demise. Attempts in sporadic AD and MCI have 
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also been made to link cognitive impairment and PIB uptake. There however does not 
appear to be a direct link between these two factors.  
 
Therein lies the possibility that other neurotoxins are at play in sporadic AD and PCA. 
Possibilities include the hyperphosphorylated tau proteins and amyloid precursor protein 
monomer and oligomers. Tau proteins are responsible for the neurofibrillar tangles seem in 
sporadic AD. Their deposition supersedes plaque amyloid along with amyloid oligomers 
correlates to cognitive decline18. Postmortum staining in PCA and sporadic AD shows similar 
distribution of tau in these cases but longitudinal studies are lacking1.  The amyloid 
oligermers are a collection of soluble proteins found in the CSF of sporadic AD subjects. 
They have neurotoxic properties and are thought to be equilibrium with fibrillar amyloid. After 
an uncertain “lag” period there is aggregation of amyloid oligomers to from proto-fibrils and 
filaments.  Unstained by PIB, their presence has yet not been demonstrated in PCA, but 
given the presence of fibrillar amyloid in would seem likely that they play as important a role 
as in sporadic AD. 
 
The data suggests a similar pathological process taking place in both sporadic AD and PCA. 
Despite this the visual disturbance experienced by PCA subjects would suggest greater 
susceptibility of this system to the toxic cerebral environment proposed to be present with 
Alzheimer’s pathology. In sporadic AD a metabolically demanding default mode network is 
thought to be affected early in the course of AD. The result is cortical dysfunction affecting 
the posterior parietal areas impairing temporo-parietal systems responsible for memory 
retrieval. In subjects with PCA, it may be that the parieto-occipital or temporo-occipital 
networks are more prone to damage and are hence affected early on before the dysfunction 
of the default system is seen. The results demonstrate impairment of the visual system 
clinically manifested by Balint’s syndrome and prosopagnosia.  
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This study does have limitations. All PCA scans showed posterior cortical atrophy. I 
however, did not apply an atrophy correction. This can potentially be identified as major 
short coming but the usefulness of atrophy correction is however a matter of debate. The 
presence of atrophy results in a partial volume effect where radioactive uptake appears 
falsely reduced19. It relates to the low resolution of PET imaging where are point source of 
radioactivity appears in the image as a 3D Gaussian distribution. This blurring effect is the 
partial-volume effect (PVE) or alternatively called intensity diffusion. PVE biases 
measurements, e.g. reducing apparent uptake levels in areas of high-uptake and increases 
apparent uptake levels in areas of low-uptake. Techniques have been used to correct for this 
blurring mathematically but findings suggest that correct for this effect only becomes 
necessary at for lesions smaller that FWHM x 3 and at low radioactivity20.  
 
For [11C]-PIB, the expansion of the posterior regions may artificially boost the signal 
producing erroneous results. This approach may have resulted in findings reported in other 
studies were [11C]-PIB uptake was higher in PCA than AD. The opposite would be true for 
[18F]-FDG. The atrophy may have resulted in the significant reductions in occipital FDG 
uptake described in PCA compared to AD. The boost in signal that results from the 
application of atrophy correction may result in the loss of these signal changes. The 
convolution of images can introduce a significant level of noise into images. A recent study 
comparing AD to PCA also utilized atophy correction but this did not produce any changes to 
results8. 
 
Another limitation of this study can however be considered to be the sample size. The 
inclusion of 8 subjects prevented potentially useful correlations between clinical features and 
PET finding to be done effectively. An increase in the sample size would also strengthen the 
power of the study. However, maintaining strict inclusion / exclusion criteria allowed me to be 
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confident that the subjects included suffered from PCA and conditions with a similar 
phenotype. 
 
4.6 Conclusion 
This study supports PCA as a variant of AD with a similar pattern of amyloid deposition. The 
difference in symptomology may however be explained by the greater reduction posteriorly 
of cerebral metabolism in PCA. The cause of this selective targeting of this part of the brain 
remains unclear but the responsible neurotoxin is also likely to play a role in sporadic AD. 
There is increasing evidence pointing towards hyperphosphorylated tau and non-fibrillar, 
soluble amyloid and the development of in-vivo biomarkers for these compounds may prove 
invaluable in investigating neuro-degeneration.   
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4.7 Tables 
Table 4.1. Demographic profile of all subjects investigated. PCA=Posterior Cortical Atrophy; 
AD= Alzheimer’s Disease; HC= Healthy Controls; MMSE=Mini-Mental State Examination; 
SD=standard deviation; PIB=Pittsburgh compound B, M = male, F = female. 
 PCA total  AD total Healthy Controls 
Total No 8 12 13 
Sex 3M / 5F 7M/ 5F 9M/4F 
Age (yrs ± SD) 60.0 ± 3.9 63.5 ± 6.5 64.8 ± 6.6 
MMSE (mean ± SD) 19.2 ± 7.2 19.6 ± 4.08 29.6 ± 0.8 
 
 
Table 4.2. Neuropsychological assessment results in the group of PCA patients.- =Not 
Impaired, ~=Borderline, + = Mildly Impaired, ++ = Moderately Impaired, +++ = Severely 
impaired 
 
 
 
 
 
 MMSE Visual 
Naming 
(GNT) 
Reading 
(WTAR) 
Verbal 
Reasoning 
(Similarities) 
Construction 
(Block 
Design) 
Visual 
Perception 
(Frag.  
Letters) 
Episodic 
memory 
(Log Mem-
Del) 
Working 
Memory 
(Digit 
Span) 
Pt1 
 
13 
+++ +++ - +++ +++ ~ ~ 
Pt2 14 +++ +++ - ++ +++ +++ ~ 
Pt3 27 - +++ - ++ +++ - - 
Pt4 27 +++ +++ - ++ +++ - - 
Pt5 15 +++ +++ - ++ +++ ~- ++ 
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4.8 Figures 
 
Figure 4.1. A –  [18F]-FDG parametric rCMRGlc image on a PCA patient 1 (Pt1), transverse 
and sagital views (left and middle), showed intense posterior hypometabolism, in occipital 
and temporo-parietal areas. B – [11C]-PIB-cerebellum ratio image on a PCA patient 3 (Pt3), 
transverse and sagital views (left and middle), showed posterior deposits, principally parietal 
and occipital areas. Both patients showed regional parietal cortical atrophy; more marked in 
case A (top right) than B (bottom right).   
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Figure 4.2. SPM t score results comparing PCA, sporadic AD and HC groups. [11]C-PIB 
results were similar in the PCA and sporadic AD groups. However a clear posterior tendency 
exists in [18]F-FDG in the PCA group when compared to both HC and sporadic AD. 
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Figure 4.3. Graphic representation of [11C]-PIB (A) and [18F]-FDG (B) results in Sporadic 
Alzheimer’s Disease (sporadic AD) and Posterior Cortical Atrophy (PCA). In both cases 
there is a tendency for greater posterior cerebral involvement in PCA but only occipital [18F]-
FDG retention is significantly different. (* p<0.05). 
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Figure 4.4. Profound impairment of visual spatial perception in PCA patients. A. Copy 
drawing of a Rey Osterreith complex figure of patient 3 (Pt3) B. Free drawing of a clock face 
of patient 1 (Pt1). 
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Chapter 5 
 
[11]C-PIB PET does not detect PrP-amyloid in 
prion disease patients 
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5.1 [11]C-PIB PET does not detect PrP-amyloid in prion disease patients  
 
In this chapter I will be turning my attention to an aggressive neurodegenerative condition. 
Prion diseases are typified by spongiform encephalopathy and the deposition of prion protein 
aggregates. Thus far, there is no in vivo biomarker for prion protein. This chapter focuses on 
the usefulness of [11C]-PIB to bind to this protein aggregate.   
 
Summary of Objectives 
Although PrP-amyloid and the amyloid β plaques found in Alzheimer’s disease are 
composed of different peptides, they share common physico-chemical properties.  [11C]-PIB 
has a well-established role as a marker of fibrillar β amyloid plaque deposition. In this study 
its usefulness as a reliable biomarker for the presence of abnormal PrP-amyloid deposition 
in human prion diseases including a patient with variant Creutzfeldt-Jakob disease (vCJD).   
 
Five patients at risk of, or affected by, prion disease underwent [11C]-PIB PET studies 
including one patient with vCJD who had a post-mortem examination 6 months following 
imaging.  Parametric maps of [11C]-PIB retention in tissue were generated using a spectral 
analysis with a plasma input function using data collected 60-90 minutes after injection.  
Regional brain distributions were compared to those of healthy controls. 
 
Summary of results 
There was no cortical, cerebellar or subcortical [11C]-PIB retention in any of the prion 
subjects (including the vCJD patient, despite the high density of cortical PrP-amyloid plaques 
subsequently seen at post-mortem) when compared to health controls. Non-specific [11C]-
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PIB binding was seen in the white matter consistent with the pattern of binding seen in 
healthy controls. 
 
Despite using a sensitive analytical method for detecting amyloid in vivo and selecting 
patients likely to have PrP deposition in the form of amyloid plaques, [11C]-PIB was unable 
to detect PrP-amyloid in vivo in a series of patients with different forms of prion disease.
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5.2 Introduction 
Prion diseases are fatal neurodegenerative disorders associated with the misfolding of prion 
protein (PrP)1.  Abnormally aggregated PrP accumulates in the brain as plaques or fibrillar 
deposits which may have the biophysical properties of amyloid.  The neuropathology of the 
prion diseases is highly variable, but certain sub-types, particularly Gerstmann-Sträussler-
Scheinker syndrome and variant Creutzfeldt-Jakob disease (vCJD) are associated with large 
PrP-amyloid plaques.  Currently there are no treatments for prion disorders that slow or halt 
the underlying disease process 2. The evaluation of putative therapeutics would benefit 
considerably from a non-invasive biomarker which directly measures the load of abnormal 
PrP in the brain.   
 
Although PrP-amyloid and the amyloid β plaques found in Alzheimer’s disease are 
composed of different peptides, they share common physico-chemical properties 3, including 
a high -sheet secondary structure and the binding of thioflavins.  As amyloid β load can be 
measured in patients with Alzheimer’s disease by use of PET and the thioflavin radiotracer 
[11C]-PIB4;5, it maybe that [11C]-PIB PET also proves to be an in-vivo marker of PrP-
amyloid. Here I will evaluate a range of patients who are affected by, or at risk of, human 
prion disease to determine if [11C]-PIB PET can reliably demonstrate the presence of 
abnormal PrP-amyloid deposition. This would be of potential clinical importance in the early 
diagnosis of these diseases and in identifying asymptomatic patients who might benefit from 
proposed therapeutic interventions, and in monitoring treatment efficacy.  
 
5.3 Methods 
Ethical approval for the study was granted by the Research Ethics Committee of the National 
Hospital for Neurology and Neurosurgery and written informed consent for participation in 
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the study was obtained from subjects.  Exclusion criteria included pregnancy, 
contraindication to MRI, history of cancer within the last 5 years (except skin and prostate), 
and patients who were unable to give valid informed consent. 
 
5.3.1 Subjects 
One patient with vCJD (PrD1, codon 129MM), 2 symptomatic patients with the P102L 
mutation (PrD2, codon 129MM; PrD3 codon 129MM) and 2 asymptomatic PRNP mutation 
carriers (PrD4, P102L, codon 129MM; PrD5, E200K, codon 129MM) (patient demographics 
in Table 5.1) were recruited into the study. Fifty per cent of mutation carriers are expected to 
be symptomatic by age 60 and 80% by age 80 years6. All subjects were referred to the 
National Prion Clinic, National Hospital for Neurology and Neurosurgery, London, U.K. and 
underwent a structured neurological assessment with mini-mental state examination at the 
time of the MRI study. 
 
Ten control subjects were also investigated. Their ages ranged from 55-75 years and group 
consisted of 6 males and 4 females. They were recruited as part of a previous study 
investigating [11C]-PIB uptake in sporadic Alzheimer’s disease7. 
 
5.3.2 MRI image acquisition  
All subjects underwent MRI examination using a GE Signa LX 1.5T MRI system (GE 
Healthcare, Milwaukee, WI) at the National Hospital for Neurology and Neurosurgery within 
1 month of the PET study.  After scout images were obtained, 3-dimensional T1W image 
data were acquired from 124 contiguous 1.5mm thick coronal slices (inversion-recovery 
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prepared spoiled gradient-echo sequence; TE 5ms, TR 35ms, flip angle 35º, matrix 
256x128, FOV 24x24cm). 
 
5.3.3 PET image acquisition 
PET studies were performed on an ECAT 962 EXACT HR+ scanner (Siemens, Erlangen, 
Germany) at the Clinical Sciences Centre, Hammersmith Hospital, Imperial College London, 
U.K.  Following a 10 minute attenuation scan, a bolus administration of up to 370MBq of 
[11C]-PIB (specific activity ≥10 GBq/µmol at injection) was given intravenously over 30 
seconds.  Images were obtained in 32 frames over 90 minutes with dynamic acquisition 
frames as follows: 1 x 30 s, 1 x 15 s, 1 x 5 s, 1 x 10 s, 2 x 30 s, 9 x 60 s, 3 x 180 s, 14 x 300 
s. 
 
Arterial cannulation was performed in each patient under local anaesthetic, to allow for 
continuous and rapid blood sampling in order to quantitate regional cerebral [11C]-PIB 
uptake. Blood was initially withdrawn every 5 minutes for the first 15 minutes after injection 
of [11C]-PIB and then at 10 minute intervals until 90 minutes.  A total of 175mls of blood was 
collected per scan.    
 
5.3.4 PET image analysis 
Parametric maps of [11C]-PIB retention in tissue were generated using a plasma input 
function and spectral analysis with data from 60-90 minutes after injection7. [11C]-PIB 
images were co-registered to each patient’s MRI, which was normalized into standard 
stereotactic space (Montreal Neurological Institute, Quebec, Canada).  A probabilistic brain 
atlas was used to create a standard template of regions of interest for sampling segmented 
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grey matter regions 8.  For analysis, six predefined cortical regions of interest were included:  
anterior cingulate, posterior cingulate, thalamus, striatum, frontal, temporal, parietal, occipital 
cortices and cerebellum.   
 
5.3.5 Statistical analysis 
Statistical analysis of ROI data was performed using SPSS for Windows version 14 (SPSS, 
Chicago, Illinois, USA).  Student t-tests were performed to assess differences between prion 
disease patients and healthy controls. 
 
5.4 Results 
The vCJD patient (PrD1) demonstrated signal abnormality in the dorso-medial thalamus 
bilaterally (pulvinar sign) on MRI at the time of [11C]-PIB PET study.  The patient died 
approximately 7 months later and the post-mortem revealed neuronal loss, spongiform 
degeneration and gliosis with extensive PrP plaque formation in the frontal and occipital 
cortices and in the cerebellum consistent with the diagnosis of vCJD (figure 5.1).  The MRI 
studies from the two symptomatic patients with the P102L mutation (PrD2 and PrD3) 
demonstrated supratentorial volume loss, particularly in the parietal lobes but no pathological 
signal change.  The MRI studies from the 2 asymptomatic patients (PrD4 and PrD5) were 
normal. 
 
There was no cerebral cortical or subcortical [11C]-PIB retention in any prion subjects. 
Findings were indistinguishable from normal controls.  See table 5.2 and figure 5.2.  Non-
specific [11C]-PIB binding was seen in the white matter consistent with the pattern of binding 
seen in normal controls. 
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5.5 Discussion 
In a range of different prion disorders, [11C]-PIB PET was unable to detect PrP-amyloid in 
vivo.  This is the largest reported series investigating the efficacy of [11C]-PIB PET as a 
biomarker in patients with prion disease and the only study to have included a patient with 
vCJD, where abundant “florid” PrP plaques were subsequently found.  I used spectral 
analysis to brain time activity curves (TACs) of [11C]-PIB uptake to produce parametric 
images of tracer binding. This method uses a plasma input function to directly compute 
volumes of distribution rather than using a brain reference area to reflect non-specific 
binding.  This approach was taken as in prion disease pathological changes can be found all 
brain regions including the cerebellum, the region most commonly used as the reference 
region in [11C]-PIB analysis. The 75 minute impulse response curve function (IRF) was used 
to generate the parametric map with spectral analysis. In sporadic AD this approach has 
previously been shown to be as sensitive for detecting amyloid deposition as Logan and 
Patlak graphical modelling approaches when a plasma input function is utilised7.  
 
The PET amyloid marker most extensively used to date is [11C]-PIB which is a neutral 
analogue of the histological dye thioflavin-T9.  Although there has been controversy about 
non-specific tracer binding in central white matter10, a recent study has shown that the 
preponderance of cortical PiB binding is to fibrillar plaques immunoreactive to both Aβ42 and 
Aβ40 and to vascular Aβ deposits.  Binding is most robust in compact/cored plaques in the 
prefrontal and temporal cortices of sporadic AD subjects5. 
  
[11C]-PIB, also known as BTA-1, has been shown to bind PrP amyloid in tissue slices when 
mice are infected with prion strains11. Methoxy-X04, a congo-red derivative will also label 
PrP amyloid in human brain samples of prion subjects verified at autopsy12.  Despite this, the 
first reports of [11C]-PIB PET in human prion diseases have been disappointing in that tracer 
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uptake was not significantly different from controls in a patient with the 6-OPRI mutation13 
and 2 patients with sporadic CJD (sCJD)14.  It is perhaps not surprising that [11C]-PIB was 
not seen in sCJD where amyloid plaques are an infrequent finding and a diffuse synaptic 
pattern of PrP immunostaining is usually found15.  In this study, we were careful to select 
patients likely to have PrP deposition in the form of amyloid plaques, such as vCJD where 
abnormal PrP is deposited in the form of rounded amyloid plaques with a dense eosinophilic 
core and patients with the P102L mutation where large multicentric PrP-amyloid deposits 
birefringent after congo red staining and strongly fluorescent after thioflavin S treatment are 
characteristically seen15. 
 
In the above two studies, [11C]-PIB retention was calculated by using a presumed normal 
region of interest (cerebellum in the 6-OPRI patient and pons in the sCJD patients) time 
activity curve as a reference tissue input function.  Whilst a cerebellar reference region for 
non-specific binding may be valid for sporadic AD, in prion disease pathology is usually seen 
in the molecular layer of the cerebellar cortex.  In this study, we ensured maximum 
discriminative power and reproducibility by using a plasma arterial input function and 
spectral analysis to generate parametric maps of [11C]-PIB binding.  Statistical comparisons 
were performed using a bank of healthy elderly subjects as controls from a previous study. 
Whilst it is recognised that amyloid deposition occurs in cognitively normal elderly subjects 
the reported frequency of this was thought not to be sufficient to bias the control group16.  
Despite these factors, we were unable to demonstrate significant [11C]-PIB retention in 
patients with prion disease in vivo. 
 
The lack of [11C]-PIB retention is unlikely to relate to reduced cortical blood flow in patients 
with prion disease as the tracer reaches equilibrium between plasma and brain17.  It is 
possible that the level of [11C]-PIB binding achieved during PiB-PET studies is insufficient 
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for adequate detection by PET in vivo.  10-30mg/kg of BTA-1 has been used to demonstrate 
in vivo PrP-amyloid in prion infected mice11 compared to 0.00006-0.0007 mg/kg used in a 
routine [11C]-PIB PET study in humans.  Finally, as binding of [11C]-PIB to PrP-amyloid is 
reversible it is possible washout occurred over a 90 minute PET study so that the late 
acquisition scans are not a true reflection of [11C]-PIB retention in prion disease. 
 
In conclusion, observations suggest that [11C]-PIB does not detect PrP-amyloid in vivo. 
Reports of other amyloid agents developed for Alzheimer’s disease that can detect PrP-
amyloid in patients in vivo 18 need further evaluation in larger cohorts with repeat imaging 
before amyloid biomarkers can be used as end-points in anti-PrP amyloid trials. 
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5.6 Tables 
Table 5.1. Demographics of subjects and controls. MMSE – Mini Mental State Examination 
 
 
 
 
 
 
 
 
 
 
 
 
PrD1 PrD2 PrD3 PrD4 PrD5 Controls 
(mean±SD) 
Age (years) 25 62 50 39 54 65.3±4.5 
Gender M F M M M 6M 4F 
Codon 129 MM MM MM MM MM - 
MMSE 25 27 29 30 30 29.9±0.32 
Disease 
duration 
(months) 
 
3 25 41 - - - 
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Table 5.2. Impulse Response Function 75min [11C]-PIB PET results for patients and 
controls. 
 
 
 
 
 
 
 
 
PrD1 PrD2 PrD3 PrD4 PrD5 Controls  (95% 
prediction limits) 
Anterior 
cingulate 
0.000121 0.000119 0.000147 0.000127 0.000173 0.000079–0.000203 
Posterior 
cingulate 
0.000103 0.000120 0.000139 0.000109 0.000120 0.000063-0.000211 
Thalamus 0.000095 0.000085 0.000112 0.000102 0.000130 0.000065-0.000181 
Striatum 0.000116 0.000118 0.000104 0.000116 0.000161 0.000088-0.000188 
Frontal lobe 0.000129 0.000117 0.000151 0.000135 0.000163 0.000078-0.000206 
Temporal 
lobe 
0.0001 0.000100 0.000131 0.0001 0.000137 0.000078-0.000198 
Parietal 
lobe 
0.000114 0.000106 0.000137 0.000114 0.000126 0.000075-0.000207 
Occipital 
lobe 
0.000116 0.000112 0.000139 0.000117 0.000153 0.000076-0.000208 
Cerebellum 0.000073 0.000087 0.000093 0.000073 0.000113 0.00006-0.000184 
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5.7 Figures 
 
Figure 5.1.  Abundant presence of prion protein plaques in the occipital cortex of the patient 
with vCJD (PrD1).  A: A section of the cortex, immunostained for abnormal prion protein with 
ICSM35, an antibody that reacts with PrP.  Note the frequent dense core plaques as well as 
abundant less compact amyloid.  The blue box indicates the approximate area which is 
shown at higher magnification in B.  B:  A higher magnification image of the area delineated 
by the blue box in A, stained with Haematoxylin and Eosin.  Note the two florid plaques with 
a dense core and radiating spicules, surrounded by small vacuoles. Scale bar corresponds 
to 480µm (A) and 120µm (B)  
 
 
Figure 5.2.  PET binding potential images at 75 minutes post-injection of [11C]-PIB. 
Background uptake in the white matter in is similar to that seen in controls in (A) patient with 
vCJD (PrD1), (B) symptomatic patient with P102L mutation (PrD2), (C) asymptomatic patient 
with P102L mutation and (D) normal control.  [11C]-PIB retention is shown in the frontal and 
temporal cortex in a typical case of Alzheimer’s disease (E) for comparison. 
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Chapter 6 
 
Adenosine2A receptor availability in dyskinetic 
and non-dyskinetic PD patients 
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6.1 Adenosine2A receptor availability in dyskinetic and non-dyskinetic PD patients 
 
Thus far, investigations have been done in neurodegenerative conditions where cognitive 
decline is a major component of symptomology. In this chapter I would like to turn my 
attention to the second most common form of neurodegeneration worldwide, Parkinson ’s 
disease (PD).  Specifically I will be looking at the biochemical changes that take place in 
levodopa induced dyskinesia (LID) in PD. Long held views in PD focused on dopamine and 
its role in motor control. Other neurotransmitter systems are invariably involved and the 
adenosine system will be investigated here.  
 
Summary of objectives 
To investigate striatal adenosine2A (A2A) receptor availability in Parkinson’s disease (PD) 
patients with and without levodopa induced dyskinesias (LIDs). Dopamine replacement with 
levodopa is a mainstay of treatment in PD. While providing effective relief from the motor 
symptoms of PD, levodopa use is associated with development of LIDs. The A2A receptors 
are expressed on the bodies of indirect pathway medium spiny striatal neurons and on 
dopamine terminals and play a role in modulating dopamine transmission. A2A antagonists 
have anti-parkinsonian activity boosting levodopa efficacy. We aimed to study A2A receptor 
availability in PD patients with and without LIDs using positron emission tomography (PET) 
and [11C]-SCH442416, an A2A antagonist. 
  
Six PD patients with and six without LIDs were studied withdrawn 12 hours from medication. 
Their PET findings were compared with 6 age matched healthy controls. Using spectral 
analysis, [11C]-SCH442416 regional volumes of distribution (VT) were computed for the 
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caudate, putamen and thalamus and binding potentials (BPND) reflecting the ratio of 
specific:non-specific uptake were compared between groups. 
 
Summary of results 
A2A binding in the caudate and putamen of PD subjects with LIDs was significantly higher 
than that of PD subjects without LIDs which lay within the control range. Thalamic A2A 
availability was similar for all three groups.   
 
PD patients with LIDs show increased A2A receptor availability in the striatum. This finding 
suggests that LIDs are associated with altered adenosine transmission and provides a 
rationale for the use of A2A receptor antagonists in the treatment of these motor 
complications. 
 
 
 
 
 
 
 
 
 
 
151 
 
6.2 Introduction 
PD is one of the most prevalent neurodegenerative disorders worldwide1.  The pathology of 
PD is characterised by the loss of dopaminergic neurons from the substantia nigra compacta 
in the midbrain with formation of Lewy body inclusions in surviving cells. Treatment has 
focused on relieving motor components of PD with emphasis placed on dopamine 
replacement. The pro-drug levodopa remains the most effective oral therapy and, in time, is 
offered to most PD patients. 
 
Use of oral levodopa in PD, however, is not without its complications. Chronic exposure is 
associated with the development of involuntary movements known as dyskinesias2. These 
include choreic movements when patients are switched “on” and dystonic posturing as 
patients switch between “on” and “off” states with rising and falling plasma dopamine levels. 
The prevalence of LIDs in PD is around 50% after 5 and 90% after 10 years of exposure to 
levodopa treatment2, 3. The development of LIDs complicates the management of PD and 
their presence has been linked to increased mortality and weight loss4.  
 
The pathogenesis of LIDs remains unclear but is linked to changes in the output of the 
striatum to the internal pallidum via the direct and indirect pathways5-7. Striatal neurons of 
the indirect pathway express A2A receptors and project to the external pallidum, which in 
turn connects to the internal pallidum via the subthalamic nuclei. Striatal neurons of the 
direct pathway project directly to internal pallidum and do not express A2A sites. 
Cynomolgus monkeys lesioned with the nigral toxin MPTP that developed dyskinesia after 
treatment with levodopa have shown significantly higher striatal A2A mRNA levels when 
compared to non-dyskinetic monkeys and a normal control group8. In humans, post mortem 
studies have demonstrated increased A2A mRNA expression in PD patients with 
dyskinesias5.  
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In this study I hypothesised that dyskinetic PD patients would have higher striatal A2A 
receptor availability compared to non-dyskinetic subjects resulting in underactivity of the 
indirect pathway. In contrast, A2A binding in the striatum of nondyskinetic PD patients would 
be similar or reduced compared to that of normal healthy controls.  
 
In this study I have made use of the tracer [11C]-SCH442416. This tracer’s chemical name 
is 5-Amino-7-(3-(4-[11C]methoxy)phenylpropyl)-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-
c]pyrimidine. It is a potent antagonist to the A2A receptor9. It is synthesised by the 
methylation of the phenol precursor [11C]methyl iodide in dimethylformamide in the 
presence of sodium hydroxide at 90°C for 4 min10. It has been used previously in rat and 
primate studies where it has been shown to bind selectively to A2A receptors11. Kinetic 
studies confirms early and sustained concentration of [11C]SCH442416 within the striatum 
of primate brains. Low binding was confirmed in the cerebellum, and area of the brain with 
low A2A receptor expression11,12. The low uptake of [11C]SCH442416 in the cerebellum 
meant that it could be used as reference region for analysis of PET data.  This is the first 
study involving the use of [11C]-SCH442416 in human PD subjects. It is hoped that this 
agent would be a useful biomarker in any future study of A2A availability.  
 
6.3 Methods 
6.3.1 Subjects 
The size of the PD cohorts and control group were determined by the previously established 
low variance of the binding potential for [11C]-SCH442416 PET (standard deviation of BPND 
~0.2 in controls).  Six PD subjects with and six without dyskinesias should provide 80% 
power at a 5% error rate to detect an effect size of ∆BPND =0.4. 
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Twelve PD patients were recruited from local Movement Disorders Clinics. All patients 
fulfilled UK Parkinson’s Disease Society Brain Bank clinical diagnostic criteria for idiopathic 
PD. Patients with significant co-morbidities including a previous history of another 
neurological condition, dementia or depression were excluded. The patient group consisted 
of two separate cohorts: six subjects had levodopa induced dyskinesias and a further six 
subjects were dyskinesia free on this medication. The effective levodopa dose for each PD 
subject was calculated as 100 mg levodopa = 2mg cabergoline = 1mg pramipexole or 1mg 
pergolide = 5mg ropinirole = 4mg rotigotine patch = 0.5mg rasagiline. The conversion factors 
below were used for controlled release levodopa and levodopa/carbidopa/entecapone 
combination: 125 mg controlled release levodopa = 65mg levodopa; 50 mg 
levodopa/carbidopa/entecapone combination = 65mg levodopa. Six age-matched healthy 
controls were also recruited. Table 6.1 summarises the clinical features of all PD patients 
and healthy controls. 
Approval for this study was obtained from the Ethics Committee of the Hammersmith, Queen 
Charlotte and Chelsea and Acton Hospitals Trust. Permission to administer [11C]-
SCH442416 was obtained from the Administration of Radioactive Substances Advisory 
Committee (ARSAC), UK.  
 
 
6.3.2 Clinical assessment 
All patients were assessed with the Unified Parkinson’s Disease Rating Scale (UPDRS). 
Assessments were performed when the patients were switched “off” withdrawn from their 
medication. 
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6.3.3 PET image acquisition 
PET scanning was performed at the Cyclotron Building, Hammersmith Hospital, London, UK, 
using a Siemens ECAT EXACT HR+ scanner. This scanner has an axial view of 15.5 cm. 
Sixty three transaxial image planes were acquired at 2.46mm slices with a reconstruction 
axial resolution of 5.4 mm and a transaxial resolution of 5.6 mm13,14. A 10 min. transmission 
scan was acquired before the emission study using a single rotating photon point source of 
137Cs for subsequent attenuation and scatter correction. This was followed by the injection of 
an average of 612 MBq of [11C]-SCH442416 over 10 seconds, 30 seconds after the start of 
a 90 minute dynamic emission scan (34 frames). The PET data, that were acquired in 3-
dimensional mode, were corrected for attenuation, detector efficiency, random events and 
scatter and reconstructed into tomographic images using filtered back projection.   
 
Prior to scanning all subjects had radial arterial cannulation under local anaesthesia.  
Continuous online sampling was performed for the first 15 minutes and then discrete blood 
samples were taken at baseline, 5, 10, 15, 20, 30, 40, 50, 60, 75 and 90 minutes. An aliquot 
of each discrete sample was rapidly centrifuged to obtain corresponding plasma and 
radioactivity concentrations that were measured in an NaI(TI) well counter for blood and 
plasma separately. The continuous blood counts were corrected using the plasma/blood 
ratio to derive a plasma input function. The plasma was further analyzed for radiolabeled 
metabolites using high performance liquid chromatography (HPLC) and the plasma input 
function was corrected accordingly to produce a final parent radioligand input function to be 
used for quantification.  A post hoc frame-by-frame realignment procedure was applied to 
compensate for head movement in the scanner. To reduce the influence of redistribution of 
radiotracer producing erroneous realignments15 non-attenuation corrected images were 
used. Non-attenuation corrected images are considered to be more useful for the 
realignment algorithm because these images include a significant scalp and skull bone 
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marrow signal compared with attenuation corrected images. Frames were realigned to a 
single, ‘reference’ frame acquired 40 mins post-injection which had a high signal to noise 
ratio, using a mutual information algorithm16 and the transformation parameters were then 
applied to the corresponding attenuation corrected dynamic images. The nonattenuation 
corrected images were denoised using a level 2, order 64 Battle Lemarie wavelet filter17. 
 
[11C]-SCH442416 was manufactured and supplied by Hammersmith Immanet, GE 
Healthcare. 
 
6.3.4 MRI image acquisition 
Each subject had a volumetric T1 weighted MRI performed with a Philips 1.5T Eclipse 
system for the purpose of defining the cerebellum, caudate, putamen and thalamus for 
sampling. The individual MR images were coregistered to the PET summed images using an 
automated multiresolution optimization procedure18. The anatomical segmentations obtained 
used to obtain the average time-activity curves of radioactivity concentration for the above 
defined regions that were then used for quantification. 
 
6.3.5 PET quantification 
Spectral analysis together with the metabolite-corrected plasma input function was used to 
analyse the kinetic components of the regional time-activity curves19,20. In brief, spectral 
analysis decomposes the regional time-activity course of the radioactivity concentration into 
separate kinetic components that are functions of the input function and of the tissue 
compartments with different residence times. The regional total volume of distribution (VT) 
can be obtained by adding the spectral analysis components detected into a suitable kinetic 
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range that encompasses the free tracer in tissue plus its binding, both non-specific or 
specific to the A2A receptors. Finally, the measure of interest, that is the binding potential of 
the specifically bound radioligand relative to the non-displaceable radioligand in tissue 
(BPND) 
21 is calculated from the volumes of distribution as:  
 BPND   =   VT 
target region / VT 
cerebellum   -   1. 
The cerebellum (which is devoid of A2A receptors in humans) was used as a reference 
region and therefore VT 
cerebellum   was used as an estimate of the free and nonspecifc binding 
of [11C]-SCH442416 throughout the brain. All pre-processing and quantification steps were 
performed using in-house routines written in Matlab 6.5 (The MathWorks Inc., Natick, MA, 
USA). 
 
6.3.6 Statistical Analysis 
Regional group differences in BPND were tested with the Mann-Whitney U statistic using 
SPSS (v.16, SPSS Inc., IBM, Chicago, IL, USA). The threshold for statistical significance 
was set at p=0.05. 
 
6.4 Results 
All patients and control subjects recruited had [11C]-SCH442416 PET scan and 1.5T MRI. 
Figure 6.1 illustrates the PET findings of the subjects scanned. The BPND of all groups are 
given in Table 6.2. The data, interrogated with the Mann-Whitney U statistic, revealed a 50% 
increase in BPND in the caudate and putamen of dyskinetic PD compared with non-dyskinetic 
PD and control groups (p<0.05). Thalamic A2A binding was equivalent in all three groups.  
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6.5 Discussion 
In this study we have demonstrated significantly higher uptake of [11C]-SCH442416 in the 
caudate and putamen of the PD patients with LIDs as compared to those without LIDs or 
healthy controls. Additionally, no significant difference in A2A binding was found between PD 
patients without LIDs and healthy controls. In the human brain, the striatum contains one of 
the highest concentrations of A2A receptors6,22,23. These are found mainly on the spinous 
processes of the medium spiny neurones of the indirect pathway22 and are G protein 
coupled. Their activation leads to inhibition of D2 receptors and an overall suppression of 
indirect pathway activity6. The increase in A2A we have identified mirrors the results of other 
studies where A2A receptor mRNA expression was shown to be elevated in dyskinetic 
patients5 and in dyskinetic animal lesion models of PD24.  
 
An understanding of how increased A2A expression could result in the production of 
dyskinesias requires an understanding of the functioning of the indirect pathway. Reference 
should be made to figure 1.6 in Chapter 1, Introduction.  Along with the direct pathway this 
system links the striatum with the globus pallidus interna (GPi)/substantia nigra pars 
reticulata (SNpr) complex via the external pallidal and subthalamic nuclei. The GPi projects 
directly to the thalamus with GABAergic output and has a final inhibitory effect on motor 
activity.  Indirect striatal to GPe neurones are GABAergic as are neurons from the GPe to 
the subthalamic nucleus while the STN to GPi projections are glutametergic.  The net effect 
of the indirect striatal output is, therefore, facilitatory on GPi and inhibitory on thalamus 
whereas the direct striatal pathway inhibits GPi and facilitates thalamic acitivity.  The A2A 
receptors are found on the neurones extending from the striatum to the GPe. Activation of 
these receptors inhibits the activation of excitatory dopamine D2 receptors6. The activity of 
the system is however complicated by the presence of collateral interneurones also 
expressing A2A receptors and exerting a negative feedback on this inhibitory system. Figure 
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1.6 summarises this and highlights the ability of A2A activation to suppress D2 activity. The 
overall effect of increased A2A influence is thought to be a reduction in indirect pathway 
activity. Thalamic activation (and subsequent activation of the motor cortex) thus becomes 
increased and disorganised potentially resulting in dyskinesia. 
 
The relationship between A2A receptor activation and dyskinesia is also influenced by other 
neurotransmitter systems. Preproenkephalin (PPE) is one such neuromodulator and 
increased PPE expression has been associated with the development of dyskinesia in 
MPTP monkeys25. PPE mRNA expression in rat striatum is facilitated by A2A activation5. 
Dyskinesia has been thought to evolve after the priming of the brain by the early use of 
levodopa. A2A activation may be a requirement for this early priming stage26. In MPTP 
primate models of PD, animals that did not developed dyskinesia had lower levels of A2A 
receptor binding and gene expression compared to those animals that developed 
dyskinesia. Abnormal opioid27 and glutamate28 transmission have also been implicated in 
previous investigations. 
 
In this study, dyskinetic subjects had a longer duration of PD, higher UPDRS scores and 
were taking higher doses of levodopa than the non-dyskinetic cases. Thalamic [11C]-
SCH442416 binding was however similar between all groups. This makes it unlikely that the 
differences in striatal binding observed are secondary to a pharmaceutical or pathological 
effect.  The increase in striatal A2A availability was thus thought to be related to dyskinesia 
onset. This study however does not inform on the cause of dyskinesia nor were we able to 
make clear correlations between clinical data and [11C]-SCH442416 binding. Larger 
longitudinal studies would be needed for this.  
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The study does however demonstrate a potential pharmacological target for the 
management of LID. Istradylline has already been introduced clinically as an A2A blocker25. 
While it was not able to suppress dyskinesias already present, it enables lower doses of 
levodopa to be used earlier in the disease. It may thus have a long term benefit in delaying 
the onset of LID. Its early use may also have an impact on the priming of the brain and 
possibly delay the LID onset. Therefore, although other neurotransmitter systems are also 
important in the production of dyskinesia, the significant abnormalities in A2A availability 
identified in LIDs suggest that effective management could include the use of an A2A 
antagonist in addition to drugs targeting other systems.  
 
Finally, [11C]-SCH442416 PET has been confirmed as a useful method for the in vivo 
investigations of A2A availability. This gent can thus function as a biomarker of A2A 
availability and would be useful when investigating dose-occupancy profiles of other A2A 
antagonists. 
 
In conclusion I have been able to demonstrate higher A2A recptor levels in the putamen and 
caudate of PD subjects with LID.This will no doubt impact on the development of future 
drugs targeting this receptor in PD. Having established the binding profile of [11C]-
SCH442416 such invasive procedures like arterial cannulation (to provide a blood input 
function) may no longer be necessary for analysis making [11C]-SCH442416 indeed. 
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6.6 Tables 
Table 6.1. Study population 
 Gender 
(M/F) 
Age 
(yrs) 
Disease 
Duration (yrs) 
H&Y 
stage 
LED 
(mg/day) 
UPDRS  
Controls 
N=6 
Mean±SD 
3/3 65 
± 
6.2 
NA NA NA NA 
PD without LID 
N=6 
Mean±SD 
4/2  67.7 
± 
4.4 
6.2 
± 
3.4 
1.9 
± 
0.4 
299 
± 
112.2 
54.7 
± 
19.7 
PD with LID 
N=6 
Mean±SD 
2/4 65.3 
± 
11.4 
13.2** 
± 
5.6 
2.8** 
± 
0.3 
1029** 
± 
477.9 
64.7 
± 
9.0 
**p<0.05  Mann-Whitney U test 
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Table 6.2. [11C]-SCH442416 Binding Potential of the three groups investigated 
Region Controls PD without 
LID 
PD with LID Control vs 
PD with LID 
PD without 
LID vs PD 
with LID 
Caudate 
Mean±SD 
0.53± 
0.24 
0.4±0.24 
 
0.96±0.46 
 
p=0.041 
 
p=0.026 
 
Putamen 
Mean±SD 
0.99±0.21 
 
0.97±0.33 
 
1.67±0.62 
 
p=0.0087 
 
P=0.036 
 
Thalamus 
Mean±SD 
0.12±0.18 
 
0.13±0.14 
 
0.14±0.18 
 
NS 
 
NS 
 
NS – not significant  
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6.7 Figures 
 
Figure 6.1. Sample PET binding potential images of [11C]-SCH442416 binding in the groups 
investigated. A – Normal healthy controls, B – PD subjects without dyskinesia and C – PD 
subjects with dyskinesia. Increased binding evident in the striatum of dyskinetic PD subjects. 
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Chapter 7 
Conclusion 
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7.1 Conclusion 
As the population ages it is clear that dementia and neuro-degeneration will play an 
increasingly important role. In this thesis I have been able to investigate potential causes 
underlying cognitive failure. Not surprisingly much of dementia work has focused on fibrillar 
amyloid plaques. However this thesis supports the concept of neuro-degeneration being 
multifactorial with many different proteins playing a role.  
 
Investigations into TBI have raised interesting questions into the importance of the amyloid 
plaque in cognitive impairment. Results were indeed surprising with on-going microglial 
activation without evidence of plaque deposition. Unexpected also was the disassociation 
between plaque deposition and reduced cerebral metabolism found in PCA.  Results of 
these investigations have supported the notion that cerebral damage occurs even without 
plaque deposition. Although in PCA, subjects may have an increased posterior cerebral 
susceptibility, it is very likely that other proteins, e.g. tau, are more neuro-toxic and are 
driving inflammation and cognitive decline. This concept is still to be proven and such 
studies would benefit from in vivo biomarkers for tau. The establishment of a spacio-
temporal relationship between tau and inflammation may indeed impact the development of 
new treatment options against tau. 
 
TBI investigations also fuel the debate of whether the microglial cell is a friend and foe. 
Regardless of the guilty protein (amyloid, tau, α-synuclein etc.) the result is the ignition of a 
cascade of events that keep microglial cells activated. By its phagocytic activities, it helps 
clear any cellular debris and deal with any aberrant protein products but is its chronic 
activation linked to actual protein deposition and neuronal death? Should treatment thus be 
targeted to the switch off these microglia and keep them switched off? The potential here is 
the developments of disease modifying treatments. Obviously caution is necessary as 
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deactivation of microglial cells can potentially increase the infection risk or worsen the speed 
of cognitive decline with reduce protein phagocytosis. Further investigations are clearly 
warranted.  
 
My investigation into A2A and LID has strengthened arguments into the use of A2A 
antagonist in the management of motor complications of PD. Thus far no effective treatment 
of LID has been identified. With further evidence of the in vivo pathogenesis in humans, the 
usefulness of the A2A receptor as a target for the development of pharmaceutical agents is 
established. SCH442416 may also prove to be a useful as a biomarker in PD and LID and 
further investigations utilising this ligand are warranted.  
 
This thesis strengthens the argument that a larger amourment of in vivo, minimally invasive 
biomarkers for the diagnosis, and follow up of dementia patients is needed. The usefulness 
of agents like PIB lies partially in their sensitivity and specificity for fibrillar amyloid. The prion 
disease study however illustrated that it cannot be relied on as a marker of other proteins 
that also form βsheet plaques. Currently a reliable in vivo marker of prion protein has not 
been established. PET however has a proven track record for being a useful tool for the 
serial investigation of protein deposition and the development of such a tracer will prove 
invaluable. 
 
This thesis has generated far more questions than answers. Results were far from expected 
and bring into question the importance of the amyloid plaque as the driving force in 
dementia. Results demonstrate a clear role for chronic microglia activation and suggest that 
imaging of other proteins e.g. tau would also be of importance. The future may thus lie in 
pursuing these concepts and they should be considered with any future drug development. 
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The use of minimally invasive biomarkers is important in the investigation of any treatment 
piloted and development must be continued to further our knowledge on especially for rare 
conditions. 
 
 
 
